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ABSTRACT 
Despite the importance of calcifications in early detection of breast cancer, and 
their proposed association with tumour growth, remarkably little detail is known 
about their chemical composition, or how this relates to pathology.  One reason 
for this gap is the difficulty of systematically and precisely locating calcifications 
for analysis, particularly in sections taken from diagnostic archives.  Two simple 
methods were developed which can achieve this in sections cut from wax 
embedded breast tissue.  These are based on micro-CT and x-ray fluoroscopy 
mapping, and were used to locate calcifications for further study. 
The elemental composition of calcifications in histological sections was 
measured using energy-dispersive x-ray spectroscopy in an environmental 
scanning electron microscope.  Variations in Ca:P ratio could in principle be 
detected  non-invasively by dual energy absorptiometry, as demonstrated in a 
proof of principle experiment.  However, the Ca:P ratio was found to lie in a 
narrow range similar to bone, with no significant difference between benign and 
malignant.  In contrast, a substantial and significant difference in Na:Ca ratio 
was found between benign and malignant specimens.  This has potential for 
revealing malignant changes in the vicinity of a core needle biopsy. 
The phase composition and crystallographic parameters within calcifications 
was measured using synchrotron x-ray diffraction.  This is the first time 
crystallite size and lattice parameters have been measured in breast 
calcifications, and it was found that these both parallel closely the changes in 
these parameters with age observed in foetal bone.  It was also discovered that 
these calcifications contain a small proportion of magnesium whitlockite, and 
that this proportion increases from benign, to carcinoma in-situ, to invasive 
cancer.  When combined with other recent evidence on the effect of magnesium 
on hydroxyapatite precipitation, this suggests a mechanism explaining 
observations that carbonate levels within breast calcifications are lower in 
malignant specimens. 
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1 Calcifications in Breast Cancer 
1.1 Current role in diagnosis 
Calcifications* have an important role in the early detection of breast cancer.  It 
is widely accepted that early detection is important; in the words of the World 
Health Organisation “Early detection of cancer greatly increases the chances for 
successful treatment”1.  A suspicious pattern of radiographically visible 
calcifications is frequently the earliest diagnostic sign of breast cancer.  In a 
recent publication from a large scale study of ductal carcinoma in-situ (DCIS) 
90.6% (1967 /  2169) of patients with a diagnosis of DCIS had screen detected 
calcifications2.  In another study, 76% of DCIS and 35% of small invasive 
tumours (< 10 mm) were detected on the basis of calcifications alone3.  
However, the presence of calcifications is also common in normal breast tissue, 
particularly in older women4.  The presence of calcifications per-se does not 
necessarily indicate the presence of breast cancer or precancerous changes in 
breast tissue.  Nonetheless, the radiographic appearance of calcifications can 
provide clues as to whether they are benign or malignant in origin.  The 
radiographic features of calcifications that are most diagnostically useful have 
evolved over decades through many radiology-pathology correlation studies.  
The characteristics which best distinguish suspicious from benign calcifications 
are based on observation of their radiographic size, shape, and distribution.  
There are well developed rules for incorporation of these observations within a 
standardised reporting and risk scoring system, such as the American College 
of Radiology Breast Imaging Reporting and Data System (BI-RADS)5, which is 
widely used in North America and much of Europe, or the Royal College of 
Radiologists Breast Group (RCRBG) classification6, which is widely used in the 
UK.  The RCRBG system is used to classify mammography and ultrasound 
findings on a simple 1 - 5 scoring system for normal, benign, uncertain, 
suspicious, and malignant appearance.  The BI-RADS system employs a similar 
                                            
*
 The term microcalcifications is frequently used to describe calcifications of less than about 0.5 
– 1mm in diameter
8,209
, since this is the size range of most interest and concern in breast 
cancer.  The umbrella term “calcifications” includes microcalcifications as well as calcifications 
of a larger size, and is generally used in this work. 
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1 – 5 scale from normal to malignant for reporting ultrasound and 
mammography results, but also includes categories of 0 and 6 for incomplete 
assessment and biopsy-proven malignancy respectively.  In addition, BI-RADS 
4 is often subcategorised into classes 4a, 4b, and 4c for low, intermediate, and 
moderate suspicion of malignancy7.   
The BI-RADS standardised report for mammography includes assessment of 
breast composition, description of any masses, asymmetry, or architectural 
distortion, and classification of the morphology and distribution of calcifications. 
Morphological descriptions of calcifications are classified as “Typically Benign” 
or “Suspicious”, are described in detail, with examples, in the BI-RADS Atlas5. 
As well as morphology, the distribution of calcifications is an important factor in 
risk scoring.  Diffuse distribution is indicative of low risk, and distributions 
categorised as regional, grouped (cluster), linear, and segmental represent 
increasing levels of risk.  Another important factor in risk scoring is the stability 
of calcifications; a pattern of calcifications that stays stable over the course of 
three screening examinations can be considered to be less suspect8. 
Despite the refinement of mammographic risk-scoring rules over decades of 
experience and hundreds of millions of mammograms*, the value of 
mammography as a routine screening tool remains highly controversial, both in 
the medical literature and in the popular press.  There are three interconnected 
reasons for this.   
First, mammography screening has a low positive predictive value (PPV).  The 
most recent published results from the NHS England screening programme 
show that only 21% women referred for further assessment following screening 
subsequently receive a diagnosis of cancer9.  Quite apart from the cost, false-
positive screening mammograms can lead to distress lasting for years, 
particularly for biopsy assessment10. 
                                            
*
 The screening mammography coverage for all OECD countries in women age 50 – 69 was 
58.8% in 2013.  With a corresponding subject population of 150 million and triennial screening, 
that equates to approximately 30 million mammograms per year. 
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Second, a significant proportion of patients participating in mammography 
screening are overdiagnosed, i.e. cancers are detected which would never have 
become symptomatic in the patients’ lifetime.  Estimates of overdiagnosis are 
notoriously difficult to make since patients who have received a diagnosis of 
breast cancer are generally treated.  The only way to be certain that an 
individual has been overdiagnosed is if she receives a diagnosis of cancer, 
remains untreated, never develops symptoms, and dies of something else.  
Indirect evidence from trials, observational studies, and statistical modelling 
have yielded widely varying estimates varying from zero to 54%, though an 
overall figure region of 11% to 22% has been suggested11.  It is generally 
accepted that overdiagnosis is a significant problem which needs to be 
addressed12, particularly with DCIS13,14.  
Third, breast cancer death rates remain stubbornly high, even in populations 
with a high uptake of screening.  Women who consistently attend screening still 
die of breast cancer.  An independent evidence review commissioned by 
Cancer Research UK and the Department of Health (England) and published in 
2002 concluded that the most reasonable estimate for reduction in breast 
cancer mortality as a result of screening is approximately 20%, with a 95% 
confidence interval of 11% to 27%15. The US Agency for Healthcare Research 
and Quality published a meta-analysis of evidence in 2016 and concluded: 
“Breast cancer mortality is reduced with mammography screening, although 
estimates are of borderline statistical significance, the magnitudes of effect are 
small for younger ages, and results vary depending on how cases were accrued 
in trials.” 11.  However, it has been suggested that much of the positive evidence 
is based on old studies conducted at a time when treatment was less effective.  
The influential Cochrane group concluded that “More recent studies suggest 
that mammography screening may no longer be effective in reducing the risk of 
dying from breast cancer”16.  Studies continue to be published casting doubt on 
the efficacy of screening for reducing mortality.  For example, a recent study 
charting breast cancer mortality against screening uptake by county in the US 
found strong evidence that screening has no effect on breast cancer specific 
mortality, with a 10% increase in screening uptake giving a mortality risk ratio of 
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1.01 (95% CI, 0.96-1.06)17.  A large randomised study in Canada with 25 years 
follow up similarly found no breast cancer mortality benefit from screening, with 
a hazard ratio for screened/unscreened of 1.05 (95% CI 0.85 to 1.30)18.   
Combining uncertain estimates of overdiagnosis and mortality reduction 
inevitably yields widely varying results on the ratio of unnecessary interventions 
to lives saved.  A typical analysis in a patient summary for the Journal of the 
American Medical Association estimated that for 50 year old women screened 
for 10 years, for every life saved by screening, 6 women receive unnecessary 
treatment (e.g. mastectomy, radiotherapy, chemotherapy), 9 have an 
unnecessary biopsy, and 613 receive at least one false-positive mammogram; 
in addition, 6 will die of breast cancer anyway, despite screening19.  It is clear 
that greatly improved diagnostic tests are needed, not only to reduce 
unnecessary biopsies (resulting from poor PPV) and unnecessary 
mastectomies (resulting from overdiagnosis), but also to detect aggressive 
breast cancers at an early enough stage to prevent recurrence, metastasis, and 
death.   
1.2 Use as prognostic indicator 
Once a diagnosis has been made, gauging the risk of progression and 
subsequent death is important in deciding appropriate treatment for an 
individual patient.  This is particularly important in avoiding overtreatment of 
early stage cancer20.  Appropriate adjuvant systemic therapy can eradicate 
silent micrometastases, but does carry substantial associated risks; it is 
therefore essential to be able to estimate metastatic risk before embarking on a 
course of potentially harmful treatment21.  Prognostic factors form the basis of 
that assessment, and predictive factors indicate which adjuvant treatments are 
most likely to be effective in that individual case.  Traditional prognostic factors 
are based on tumour stage and grade, and are frequently combined into a 
numerical score such as the Nottingham Prognostic Index22 for invasive breast 
cancer.  In addition, immunohistochemical (IHC) markers of oestrogen and 
progesterone receptor expression, HER2 status, and Ki67 proliferation index act 
both as prognostic indicators and predictors of particular adjuvant treatment 
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effectiveness.  In addition to a single index, prognostic factors have been 
modelled using cancer registry data and built into publicly available prognosis 
calculators such as NHS PREDICT23,24.  An important class of new predictive 
indicators is based on gene expression profiling.  The seminal paper on the use 
of this technique to create “molecular portraits” of breast cancer was published 
in 2000 in Nature25.  It has since been widely accepted that breast cancer 
develops in distinct subtypes with a similar pattern of gene expression in each 
group.  These subtypes appear to be intrinsic to the tumour; not only does the 
subtype of the primary stay within the same grouping over time, but lymph node 
metastases exhibit the same gene expression pattern as the corresponding 
primary tumours.  These different groups vary dramatically in prognosis.  A wide 
range of multi-gene expression signatures have been commercialised as 
prognostic indicators, based on expression patterns of a selected panel of 
genes26. 
Although extensively used, traditional prognostic indicators have their 
limitations.  In particular, histological grade has been widely criticised for lack of 
reproducibility27. A large scale analysis of interobserver agreement in breast 
pathology reporting comes from an analysis of  data gathered by the UK 
NHSBSP External Quality Assessment (EQA) scheme28.  Agreement on 
histological grade of invasive carcinoma was only moderate (κ = 0.47), and 
agreement on nuclear grade in DCIS was even lower (κ = 0.36);  this is 
particularly problematic, since DCIS is where the need is greatest for accurate 
prognostic and predictive information29.  A review of 12 other studies from 
around the world on inter-observer and intra-observer agreement of breast 
cancer histological grade gave broadly similar results27.  There is a clear clinical 
need for more reliable prognostic indicators.  Molecular subtyping was initially 
heralded as a new dawn for assessing breast cancer prognosis30, and 
subsequently attracted a great deal of research.  Although this has undoubtedly 
improved our understanding of breast cancer biology, agreement on risk 
categories between different commercially available gene signatures is only 
moderate31, and these have so far made limited headway in routine clinical 
practice26,32. 
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Calcifications have a role to play not only as a diagnostic sign, but as a 
prognostic indicator.  There are numerous studies showing that calcifications 
are associated with other prognostic indicators33.  However, there is evidence 
that calcification morphology has prognostic value, independent of 
histopathology classification.  In a long term outcome study, Tabár et al found 
that patients with “casting” type calcifications (“fine linear / branching” in current 
BI-RADS terminology)  have a substantially poorer long term survival compared 
to patients with either no calcifications or calcifications not classified as 
casting34.  Moreover, the prognostic value was greatest in the smallest tumours 
(< 5 mm), where traditional prognostic factors perform poorly.  This observation 
proved somewhat controversial at the time, with a surgeon involved with the 
development of the Nottingham Prognostic Index responding that “Calcification 
as a method of prognosis is not as accurate as other methods and has no 
practical clinical use”35.  A further five studies have corroborated the poorer 
outcome associated with casting calcifications36–40, though two did not find a 
correlation41,42.  A recent analysis of long term survival in younger women 
(mean age of 44.8 years at diagnosis) showed that radiological comedo 
calcification maintained independent prognostic significance in a multivariate 
analysis (in stepwise elimination of non-significant variables), whereas 
histological grade did not39.  One possible factor is that these type of 
calcifications appear to be associated with multifocal, diffuse growth, and hence 
are difficult to excise completely, resulting in increased incidence of local 
recurrence43–45.   
Given the lack of concordance within both traditional prognostic indicators and 
gene expression signatures, there is clear clinical need for better prognostic 
information to aid treatment decision making.  This is particularly true for the 
increasing number of early stage cancers detected by mammography.  
Calcification morphology has shown to have some value.  The potential role of 
calcification chemistry as a prognostic indicator remains unexplored. 
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1.3 Calcification imaging 
Since the early days of mammography there have been advances in both x-ray 
source and detectors which have improved calcification visualisation.   
The base technology for x-ray generation, consisting of a rotating anode x-ray 
tube with a molybdenum or rhodium-surface anode, has remained essentially 
unchanged since the earliest dedicated mammography units produced in 
196646.  Improvements have been evolutionary rather than revolutionary.  Tube 
design advances have allowed modest increases in power density without 
damaging the anode. This is desirable for two reasons.  The spot size can be 
made smaller, improving the resolution, which is important for 
microcalcifications, or the power can be increased, shortening exposure and 
thus reducing the potential for motion blurring, or a combination of both.  There 
is little prospect of significant further improvement in power density with 
conventional x-ray tube technology due to intrinsic thermal limitations47.  One 
recent breakthrough technology for x-ray generation involves the use of a liquid 
metal jet anode.  This could potentially increase power density by two orders of 
magnitude, and has been proposed for use in mammography47.  Liquid metal-jet 
tubes have been supplied commercially since 2010 and a range of sources 
developed.  These have been used for applications such as real-time SAXS48, 
and high resolution CT imaging of small animals using both absorption and 
phase contrast49,50.  This technology has not yet been adopted for clinical use. 
In contrast to the incremental changes in x-ray sources, improvements in 
mammography x-ray detection and imaging have been punctuated by major 
step changes in technology.  In the early days of mammography, x-ray film was 
used directly to create an image.  This required a long exposure, which not only 
was susceptible to motion blurring, but resulted in a high radiation dose.  The 
introduction of rare-earth intensifying screens in the early 1970s greatly reduced 
the time and dose required to create an image.  More recently, high resolution 
amorphous semiconductor digital detector panels have almost entirely 
superseded film.  These provide a further reduction in x-ray dose, as well as 
offering improved dynamic range, ease of postprocessing for image 
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enhancement, easier storage and retrieval, and facilitating computer aided 
detection.  Most recently, photon counting detectors are starting to be used 
clinically, most notably in the Philips Microdose system, offering further 
reduction in x-ray dose and enabling single-shot spectral mammography.   
Improvements in mammography equipment technology, particularly the 
transition from screen-film to digital mammography, have undoubtedly improved 
the detectability of calcifications51, particularly those presenting as small 
clusters52.  Several studies have suggested that the increase in detection does 
come at the expense of an increased number of false positives53,54, particularly 
during the transition period from screen-film to digital51,55.  However, other 
studies have found that the increased number of referrals for biopsy is not 
accompanied by a decrease in the percentage that are malignant3,56,57, and that 
the proportion that are of low grade has also not increased56.  Irrespective of the 
effect on predictive accuracy, it is generally agreed that digital mammography 
does overall result in increased early detection of potentially life threatening 
tumours. 
Further improvements in x-ray imaging technology undoubtedly have a 
contribution to make towards accurate early detection of breast cancer.  In part, 
this may simply be increased clarity and spatial resolution of conventional x-ray 
absorption images. However, new technology may enable more information to 
be extracted from mammographic images, using techniques such as spectral 
imaging and analysis of coherent scatter. In particular, the ability to distinguish 
between calcifications based on chemical composition rather than just size and 
morphology may add a new dimension to the information being assessed, 
resulting in both fewer false positives and an increased mortality reduction 
through earlier detection. 
1.4 Deposition mechanism 
Calcium deposits in soft tissue can occur in damaged or diseased tissue, and 
frequently occur in necrotic tissue58.  In breast tissue, fat necrosis resulting from 
external trauma, or from previous biopsy or surgery, frequently leads to 
calcification formation59.  In breast cancer, calcifications occur in conjunction 
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with comedo necrosis in DCIS, in which lack of vascular supply to proliferating 
tumour cells within a duct leads to cell death, particularly in the centre of the 
lumen60.  Calcifications can also form following neoadjuvant therapy to shrink 
the tumour prior to surgery; It is thought that these occur as a result of tumour 
cell necrosis61.  Although necrosis undoubtedly plays a role in the formation of 
some calcifications, there is increasing evidence that calcification formation in a 
breast tumour can be an active cell-mediated process, involving the expression 
by cancer cells of numerous proteins involved in bone formation and growth.  
For instance, Bone Morphogenic Protein 2 (BMP-2) promotes bone formation 
and plays an important role in osteoblast differentiation.  It has also been found 
to enhance calcification in-vitro in a malignant mammary cell line62.  BMP-2 is 
known to be expressed by breast cancer cells, and one study showed reduced 
levels in cancers without calcifications and increased levels where calcifications 
were present63.  As another example, Bone Sialoprotein (BSP) is an abundant 
bone matrix protein, which is particularly strongly expressed by osteoblasts at 
the site of new bone formation64.  Elevated expression of BSP is also found in 
malignant breast tissue, particularly where calcifications are present65.  Elevated 
levels are also associated with increased risk of bone metastasis66.  At least 
another eleven bone matrix proteins have been identified which may have an 
effect on calcification formation in the breast, though very limited research has 
been conducted on many of these
64
.  Given the diversity in gene expression 
patterns forming the basis of tumour molecular subtypes, and the fact that some 
of these expressed genes are involved in bone metabolism, it is reasonable to 
expect tumour heterogeneity to be reflected by some variation in the nature of 
the calcifications formed in different types of breast tumour.   
1.5 Proposed role in tumour growth and metastasis 
As well as being the product of cell mediated processes, there is increasing 
evidence that calcifications in breast cancer may play an active role in 
mitogenesis, upregulation of gene expression, and enhanced migration of 
tumour cells 67–69.  In particular, calcifications associated with breast cancer 
consist predominantly of hydroxyapatite, and there is evidence that nanoscale 
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properties of hydroxyapatite may play an important role in regulating breast 
cancer cell behaviour 70.  Understanding the nature of calcifications is important 
in developing a complete picture of the factors affecting tumour development 
and progression.   
In addition, the presence and nature of calcifications may be relevant to 
metastasis.  It was noted in the 19th century that cancer metastases are not 
randomly distributed through the body, but targeted at particular tissue types.  
Bone is the most common, and often the earliest, metastasis site for breast 
cancer.  The hypothesis popularised by Paget in 1889 (though suggested by 
others earlier) suggests that particular tissues form congenial “soil” in which 
circulating tumour cell “seeds” can lodge and grow71.  It is now widely 
recognised that circulating tumour cells cannot readily colonise a foreign 
microenvironment, and that “The differences in stromal components, tissue 
organization, matrix composition, and cytokine environment all impose immense 
threats on the just arrived cancer cells.”72.  The term “osteomimicry” has been 
coined to describe the way in which tumour cells can enhance their ability to 
survive and multiply in bone tissue by acquiring a bone-cell-like 
phenotype62,73,74.  In particular, prostate and breast cancer cells can adopt a 
resemblance to osteoblasts by expressing bone matrix proteins.  As previously 
noted, these proteins can induce mineralisation of breast tissue.  Breast 
calcifications may therefore be, at least in part, the product of tumour cells pre-
primed to survive in the bone microenvironment.  It used to be thought that 
metastatic spread was a late event following development and growth of a 
primary tumour.  However, it is increasingly evident that systemic spread can 
occur as an early step in breast cancer75.  This might in part explain why, 
despite the early detection and treatment of tumours as a result of screening, 
there has been a very limited reduction in breast cancer mortality.  Early 
recognition of calcifications which are the products of osteoblast-like 
metastasis-ready tumour cells may help improve the mortality benefit of 
screening. 
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1.6 Composition 
Most publications referring to the composition of breast calcifications regurgitate 
the assertion that calcifications can be categorised as two types:  Type 1, 
composed of calcium oxalate in the crystalline form of weddellite, and Type 2, 
composed of calcium phosphate in the crystalline form of apatite.  Estimates of 
the comparative frequency in breast tissue vary widely.  The proportion of 
biopsy samples with at least some Type 1 calcifications has been variously 
reported as 0.4%76, 7.3%77, 12%78, 13%79, 17%80, 25%81, and 29%63.  In large 
part the wide variation is likely to be due to patient selection for biopsy, and 
specimen selection within those biopsies.  In addition, it is known that some 
calcifications are lost on sectioning82.  Type 1 calcifications are typically larger 
and more crystalline than Type 283, hence may be more prone to loss from 
histological sections. 
It is also frequently repeated that Type 1 calcifications are typically associated 
with benign lesions whereas Type 2 are sometimes associated with cancer.  
Type 1 calcifications appear to be the result of benign secretory processes, 
particularly related to benign apocrine metaplasia79 or lobular carcinoma in-situ 
(LCIS)84. However, this does not preclude Type 1 calcifications from being 
coincidentally present as bystanders within breast tumours, as has been 
observed clinically85,86.  An interesting new perspective comes from a recent 
study showing that the total oxalate content is apparently almost 10 times 
higher in human breast tumour tissue than normal breast tissue, and that 
calcium oxalate microcrystals can generate tumours when injected into the 
mammary tissue of mice87.  These data appear to conflict with the observation 
that calcium oxalate calcifications are more common in benign than malignant 
breast lesions, but may indicate that calcium oxalate calcifications are not as 
benign as was previously thought. 
The elemental composition of breast calcifications has been measured using 
SEM/EDS, mostly in the 1970s and 1980s.  These studies were all qualitative, 
simply identifying the elements found.  In most cases only calcium and 
phosphorus were reported88–91, though small quantities of S, Si, Na, Mg, Cl, and 
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K have also reported84,92.  One study reported particles containing a rather 
implausible array of elements including Cr, Pb, Ag, Au, and Mo93, and another 
reported a calcification containing a substantial proportion of Sn94. These are 
very likely to be misidentifications, which can easily happen with automated 
peak identification in EDS software, particularly for minor elements95.  To date 
there has only been one semi-quantitative study of the composition of breast 
calcifications.  The Ca:P ratio was measured in three benign and two malignant 
Type 1 calcifications96, but with no significant difference with pathology.  Apart 
from that, quantitative elemental composition of the most cancer-relevant Type 
2 calcifications remains entirely unexplored. 
Fourier Transform InfraRed (FTIR) spectroscopy and Raman spectroscopy 
have been used to probe the relationships between calcification chemistry and 
pathology.  This complements elemental analysis, since vibrational 
spectroscopy gives useful information on the nature, concentration, and 
environment of the anions (e.g. phosphate, carbonate, hydroxide), but gives 
almost no information on the cations present (principally calcium).  Possible 
uses of vibrational spectroscopy of calcifications as an aid to diagnosis are 
outlined in section 1.7.2. 
Given the great diversity in calcification morphology, it would be surprising if all 
calcifications were of uniform chemical composition.  In addition, a wide range 
of chemical changes occur in tumour tissue, hence it is reasonable to expect 
that calcification chemistry may also vary with pathology. 
1.7 Potential new diagnostic methods 
Suggested new diagnostic methods based on calcification composition can be 
divided into two categories:  x-ray methods, and vibrational spectroscopy. 
1.7.1 X-ray based 
Conventional x-ray diagnostic methods rely on simple absorption imaging.  
Absorption is only one of many ways in which x-rays interact with matter; there 
is potential for other interaction mechanisms to be exploited for improved breast 
cancer detection. One category that has been the subject of considerable 
 13 
research over the last two decades comes under the umbrella term “phase 
contrast imaging”.  These techniques make use of phase shifts resulting from 
differences in the refractive index of different materials.  At clinically relevant x-
ray energies, phase contrast can be much larger than absorption contrast97.  A 
wide range of x-ray phase contrast techniques have been developed, with an 
even wider range of names.  The main focus of research into phase contrast 
mammography has been improvement in visualisation of subtle soft tissue 
distortions and masses.  One of the most promising techniques for practical 
clinical application is based on an adaptation of a Talbot-Lau grating 
interferometer98.  The key adaptation allowing this to be used with a 
conventional x-ray tube is the interposition of a third grating in front of the 
source.  This effectively creates an array of individually coherent sources.  A 
spin off from this approach is that a dark field image can be simultaneously 
generated, based on the strong small-angle scattering produced by microscopic 
density fluctuations99.  This dark field image has considerable potential for 
imaging calcifications.  In one study, a dark field image of an excised specimen 
clearly showed a tumour that was invisible with mammography or specimen 
radiography, but was found to contain a cluster of very small calcifications of 1 - 
40μm in size100.  Simulations demonstrated that these calcifications could 
produce the observed dark field image.  Other studies using this type of dark 
field imaging on excised tissue have successfully differentiated between Type 1 
and Type 2 calcifications101 and between Type 2 calcifications of varying  
morphologies / microtexture102.  Micro-CT measurements have suggested that 
there may be a difference in internal structure between benign and malignant 
calcifications103. One current obstacle to the implementation of this technique 
for mammography is the high tissue absorbed dose in the experimental 
configurations used to date.  However, dose was not a consideration in the 
proof of concept experiments, and it has been suggested that optimisation could 
reduce the dose to within acceptable limits102.  Another challenge is that the 
phase grating and the absorption grating need to be very precisely spaced and 
aligned.  An intriguing low-tech approach has been proposed which does not 
require gratings, but makes use of “the remarkable properties of speckles” 
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generated by scanning a sheet of abrasive paper between source and object104.  
As with the Talbot-Lau approach, this can also simultaneously create 
absorption, phase contrast, and dark field images using a microfocus x-ray tube 
source. 
Another proposed technique for non-invasive differentiation of Type 1 and Type 
2 calcifications is also based on scatter, but takes a very different approach.  
This involves energy dispersive x-ray diffraction, using a polychromatic pencil 
beam source and a photon counting detector at a fixed angle.  The sample was 
rotated in the beam and a CT slice reconstructed. This successfully 
differentiated hydroxyapatite from calcium oxalate in a phantom study105.  There 
are practical problems involved in translating a method based on a pencil beam 
into clinical use, though these may not be insuperable. 
Another potential method for distinguishing between calcifications of differing 
composition is dual energy absorptiometry.  This has been suggested as a 
method for differentiating between Type 1 and Type 2 calcifications106,107, and is 
extensively dealt with in Chapter 3. 
Methods for extending x-ray screening beyond simple absorption imaging 
appear to have potential for widening the range of information available to a 
radiologist.  In particular, information on composition, crystallography, and 
microtexture of calcifications could be diagnostically useful. 
1.7.2 Vibrational spectroscopy 
Vibrational spectroscopy has been investigated as a method to probe the 
chemistry of calcifications and thus add a new dimension to the characteristics 
used in diagnosis.  The level of carbonate substitution in hydroxyapatite has 
been shown to be significantly different between benign and malignant 
calcifications108. The carbonate level decreases sequentially from benign to 
ductal carcinoma in-situ, to invasive cancer, and in the carcinoma specimens, 
carbonate substitution is negatively correlated with histological grade109. Raman 
spectroscopy could in principle be used non-invasively to measure these 
variations in chemistry.  Conventional backscattering Raman spectroscopy is 
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too surface sensitive to interrogate the composition of calcifications buried 
within breast tissue.  Three approaches have been attempted to overcome this.  
Firstly, temporal gating of the Raman signal has been successfully used to 
probe the chemical composition of calcified materials buried up to 1mm in 
tissue.110  However, this depth penetration is insufficient for transcutaneous 
probing in the breast, and the instrumentation required is complex and 
expensive.  In addition, there are some safety concerns over the use of short, 
high power laser pulses.  Interest has shifted therefore to spatially offset Raman 
spectroscopy (SORS), in which depth discrimination is achieved by laterally 
offsetting the laser source and the signal detector.  This has been shown to be 
capable of measuring the level of carbonate substitution in hydroxyapatite 
buried in up to 8.7 mm of tissue111.  In mammography, the average compressed 
breast thickness is in the region of 60 mm,112 though it should be noted that a 
small probe applied to the skin could attain a greater local compression.  
Another approach that eliminates depth sensitivity is transmission Raman, since 
the overall tissue propagation distance of probe signal plus Raman signal is 
equal to the total tissue thickness, irrespective of the depth at which the Raman 
interaction occurs.  This has been shown to be capable of discriminating 
between hydroxyapatite and calcium oxalate monohydrate embedded within a 
total tissue thickness of up to 27mm113.  This is verging on a clinically relevant 
thickness range.  Raman spectroscopy has also been proposed as a method for 
improving the targeting on microcalcifications during needle biopsy. Real-time 
feedback could help to ensure that tissue containing radiographically suspicious 
calcifications is accurately targeted, and would reduce the chance of false 
negative samples114. 
For any of these potential adjunct methods to be clinically useful, it is necessary 
to determine and explain the relationships between calcification physico-
chemical properties and the increasingly multi-dimensional ways in which breast 
cancer pathology is classified. 
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2 Locating Calcifications in Tissue Specimens 
2.1 Aims 
A significant obstacle to the in-vitro analysis of breast calcifications is the lack of 
a simple method for systematically and precisely locating calcifications within a 
specimen.  It is often difficult to identify a calcification definitively from its visual 
appearance in the absence of staining, particularly from a macroscopic view.  
The first stage of this research was therefore to establish such a method.  This 
chapter is largely based on a previous publication115. 
2.2 Introduction 
2.2.1 Radiography 
The most direct method for locating calcifications within a histological section is 
to take an X-ray image.  Calcifications contained within a thin histological 
section would be difficult or impossible to locate in this way when mounted on a 
standard microscope slide or on a typical substrate used for infrared (IR) 
spectroscopy, such as a calcium fluoride or barium fluoride window.  In 
principle, it is possible to take an X-ray image of an adjacent histological section 
mounted on a thin radiolucent substrate such as a polymer film.  In order to 
obtain sufficient contrast in a typical histological section of 3 to 8 µm thickness, 
it would be necessary to use soft X-rays for imaging, ideally just above the 
calcium k-edge at 4.0 keV.  Generation, transmission, and detection of such soft 
X-rays is not straightforward in practice. In addition, some fragmentation and 
loss of calcifications can occur on sectioning,82 which means that some 
calcifications may be present in the spectroscopic section, but not in the 
reference radiographic section, or vice versa. 
Since taking X-ray images of the thin tissue section itself presents some 
difficulty, another option is to radiograph the whole specimen from which the 
section is to be cut.  This is a useful method for identifying which specimens 
contain calcifications, prior to sectioning.  Radiography of biopsy specimens is 
routine in clinical practice.  However, a single radiograph cannot be relied upon 
to locate the positions of calcifications in cut sections, since it gives no 
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information on the depth of these within the specimen.  Additional radiographic 
views can help, though overlaps can make correlation of views difficult.  A 
logical extension from taking multiple views is to conduct a CT scan, which can 
give a complete 3D view of the positions of calcifications in the specimen.  The 
reconstructed volume can be used to determine the expected position of 
calcifications in the cut sections.  This was therefore chosen as one of the 
methods to explore. 
2.2.2 X-ray Fluorescence 
An alternative approach is to create a spectroscopic map of entire sections.  
With many spectroscopic techniques, particularly infrared, mapping multiple 
samples at sufficient resolution to detect calcifications can be very time 
consuming.  A more suitable technique is X-ray fluorescence (XRF), which can 
relatively simply create a calcium map.  As with X-ray absorption imaging of thin 
sections, this cannot be conducted on cut sections mounted on a typical 
substrate used for IR spectroscopy.  Calcium fluoride is obviously unsuitable as 
a substrate for calcium imaging, and barium fluoride gives an excessive 
background signal which makes detection of the calcium signal difficult.  As with 
CT, a simpler method is to create a map of the block face from which sections 
are cut.  XRF images were taken, not only to investigate this as an alternative 
method, but as corroboration of the presence and position of the CT- detected 
calcifications. 
2.2.3 Coordinate registration 
XRF and CT can be used qualitatively to relate calcification position to tissue 
features.  However, in order to relate the positions quantitatively to coordinates 
within a section, it is necessary to use fiducial markers.  Various markers for 
aligning histological sections in 3 D reconstructions have been proposed since 
the early 20th century.  One of simplest methods consists of small parallel holes 
drilled through the tissue at right angles to the surface116. Various improvements 
have been suggested such as use of a laser to drill the holes117 or the use of 
markers made from such exotic materials as cactus spines118 and cuttlefish 
ink119.  In contrast to most studies on such marker systems, the aim in this case 
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is not to align serial sections, but to register the positions of features in a 
histological section to an image slice taken through a CT volume or a block face 
XRF image.  Nonetheless, the general requirements identified in earlier work 
still hold; the markers must be easy to cut, adhere to the slide, and be visible in 
the required imaging mode.   
The situation is simpler with many analyses of calcifications within formalin fixed 
paraffin embedded (FFPE) breast tissue, since cut sections are frequently not 
de-waxed.  The reason is that calcifications are held in place on the substrate 
by the wax, and de waxing can result in their loss.  In addition, acquisition of 
data from tissue embedded in paraffin can reduce the incidence of dispersive 
artefacts120. That means that simple holes in the wax surrounding the tissue can 
be used as markers, without disturbance to the tissue or the need to introduce 
foreign materials into the block.  That is the approach taken in this study, though 
other marker systems proposed in the literature could readily be substituted. 
2.3 Materials and Methods 
2.3.1 Samples 
Formalin Fixed Paraffin Embedded (FFPE) core biopsy breast specimens were 
selected from the Gloucestershire Hospitals NHS Foundation Trust diagnostic 
archive, based on the presence of calcifications in the histopathology report.  
These were screened by mounting the blocks in a Nikon Metrology XT H225 CT 
system and imaging at 20 kV both perpendicular and parallel to the face of the 
block.  Following screening, 12 blocks were selected with significant levels of 
calcification at or near the cut surface. 
A minimum of three marker holes of Ø0.4 mm were drilled in the selected 
blocks in a pattern surrounding the tissue.  Care was taken to ensure that the 
hole patterns did not have line or rotational symmetry, to ensure that it was 
possible to determine unambiguously the orientation of cut sections, and which 
way up they had been mounted on the slide or substrate. 
Two sequential microtome slices of 3 µm were cut from each block and 
mounted on Ø30 mm x 1 mm barium fluoride discs (Crystran Ltd., Poole) and 
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standard microscope slides respectively.  The latter underwent standard 
haematoxylin and eosin (H&E) processing, and were used for reference. 
2.3.2 CT scanning 
The FFPE blocks were CT scanned in the Nikon XT H225 system at 30 kV*, 
using 721 projections, and a geometric magnification of 6.0 x, giving a voxel 
size of 33 µm.  The volume was reconstructed using Nikon CT Pro 3D software. 
The reconstructed volumes were then processed using an ImageJ121 script (see 
Appendix E).  This involved cropping and rotating the volume to define the z 
axis as perpendicular to the cut face and the y axis parallel to the cutting 
direction, and applying a scale using the calculated voxel size.  The first 
complete image slice from the face of the block was selected and used to 
determine the position of the calcifications and the fiducial markers. Ellipses 
were fitted to a thresholded image to determine the marker positions, and the 
centroid used as the xy position of each hole.  The image was then thresholded 
again to isolate the calcifications, and the centre of the mass of each output to a 
text file. 
2.3.3 X-ray fluorescence imaging 
XRF imaging of block faces was conducted using a SII NanoTechnology (now 
Hitachi) SEA6000VX.  Mapping was conducted at 15 kV, with a collimator size 
of 0.2 x 0.2 mm, collection time of 50 ms per pixel, and at pixel size of 30 -  50 
µm.  Calcium Kα maps were overlaid on a white light blockface image of the 
same area captured in the XRF scanner. The machine was freshly calibrated 
with a test target to ensure x-ray beam and visual image were accurately 
aligned. 
2.3.4 Visible imaging 
The list of hole and calcification positions generated by the CT scans was used 
to determine the expected positions of calcifications on the stage of a Perkin 
                                            
*
 An accelerating voltage of 30kV was found to be an acceptable compromise between contrast 
and exposure time.   
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Elmer Spotlight 200 FTIR microscope.  The positions of the holes were 
measured, and the coordinate system of the CT-derived positions transformed 
to give a least-squares best fit of the holes to their measured positions.  This 
manipulation included scaling coefficients parallel and perpendicular to the 
cutting direction, as well as rotation and translation.  The hole centre positions 
under the microscope were determined initially by eye, which enabled the 
calculated coordinates to be entered directly into the Perkin Elmer Spectrum 
Image software to drive the stage to the calculated position of the selected 
calcification.  White light transmission maps of the specimens were also 
analysed to determine the accuracy of the calculated positions.   
2.4 Results 
2.4.1 Qualitative results 
A comparison of thresholded CT images and XRF overlay images of typical 
specimens is shown in Figure 2-1.  It can be seen that there is very good 
qualitative agreement in the position of calcifications relative to the tissue 
outlines.  The benefits of CT and XRF localisation of calcifications are illustrated 
in Figure 2-2.  It is not obvious from inspection of either the H&E slide (Figure 
2-2a) or the unstained tissue (Figure 2-2b) whether there are any calcifications 
present.  In contrast the CT image (Figure 2-2c) at the same magnification 
clearly shows the location of the calcifications.  Comparison with a magnified 
view of the unstained tissue (Figure 2-2e) enables these to be located.  Even in 
this view, it is doubtful that these features could have been definitively identified 
as calcifications without CT or XRF views. Examination of the same locations 
on the H&E slide (Figure 2-2d) shows that in both cases, the calcifications have 
largely been lost on processing.   
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Figure 2-1: Thresholded CT images and XRF overlay images of three typical 
FFPE core biopsy breast specimens. The registration holes are clearly visible on 
the CT slice images, but are less easy to locate on the XRF overlays. 
Registration holes 
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(a) H&E stained, whole section 
 
(b) Unstained, whole section 
 
(c) Thresholded CT image showing location of 
calcifications in red. 
 
(d) Stained image of area outlined in b.  
Calcifications are not apparent 
 
(e) Unstained image of area outlined in b. 
Calcification positions shown by arrows 
Figure 2-2:  Standard H&E stained and 
unstained tissue sections illustrate the 
difficulty of identifying the location of 
calcifications without the aid of a CT 
image. 
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2.4.2 Quantitative analysis 
The calculated stretching coefficients from the fitting algorithm revealed that the 
cut sections were all slightly compressed in the cutting direction.  The average 
length change in this direction was 6.7% (95% CI 8.3% to 5.2%).  The average 
change perpendicular to the cutting direction was small and not significant 
(0.4%, CI 1.8% to 1.0%).  The phenomenon of microtome induced section 
distortion has been sporadically investigated over many decades, and is 
reviewed by Jones et al.
122
  As with the early studies on the subject, 
compression occurred in the cutting direction. 
The transformed best fit hole positions were a median of 0.064 mm from the 
measured positions (max 0.22 mm).  The predicted position of 31 calcifications 
within the sections was calculated and a comparison made to the centroid of the 
corresponding calcification as measured from white light transmission images 
using ImageJ.  Calcification centroids were a median distance of 0.12 mm from 
the location calculated from the hole positions.  Typical examples are shown in 
Figure 2-3.  With five calcifications, this distance exceeded 0.25 mm (max 
0.64mm).  Four of those were in one specimen, which contained a large linear 
calcification of approximately 2mm long towards one side of the block, which 
was disrupted on cutting and may have caused shear distortion of the whole 
section. 
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Figure 2-3 CT‐derived coordinates of four calcifications overlaid on a white light 
image of an unstained section. 
2.5 Discussion 
Both CT scanning of tissue blocks and XRF mapping of the block face proved 
invaluable for locating calcifications within archive FFPE breast tissue 
specimens and relating this location to a position on a cut section.  In many 
cases, relating the position visually to the tissue outline is sufficient to locate the 
calcifications.  However, use of fiducial markers has been shown to be capable 
of providing coordinate locations with sufficient accuracy to locate the 
calcifications visually, despite distortion of these thin tissue sections.   
There are advantages and disadvantages to both methods.  In CT images, both 
tissue outlines and fiducial markers are clearly visible, allowing the spatial 
relationships to be measured directly.  This can be seen in Figure 2-1.  On the 
other hand, the tissue outline is not directly visible in the XRF maps, requiring 
an additional step of registering a visible block face image accurately to the 
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XRF map and overlaying the images.  However, fiducial markers could in 
principle be located directly by XRF if they contain sufficient concentration of an 
XRF detectable element (typically Z ≥ 12).   
Ideally these techniques should measure a thin layer within the specimen which 
is representative of the microtomed section.  With CT, it is possible to select an 
image slice at an appropriate depth beneath the block surface.  Note that even 
though archive blocks have been trimmed to expose tissue and diagnostic 
sections previously taken, some facing is still necessary to clean up the surface 
before the first complete and cohesive sections can be taken. This is typically a 
few tens of micrometres beneath the surface.  Although this CT image slice is 
thicker than the section thickness (33 µm cf. 3 to 8 µm), it is still substantially 
smaller than typical dimensions of a microcalcification.  XRF derives the calcium 
signal from a surface layer of the block, the thickness of which depends on the 
attenuation of the overlying material.  The linear attenuation coefficients of 
calcium Kα radiation (3.7 keV) within breast tissue and cortical bone (a 
reasonable analogue for breast calcification) are 92 cm-1 and 328 cm-1 
respectively.123  About 90% of the XRF signal therefore comes from the top 70 
µm of a microcalcification, though a 90% attenuated calcium signal may be 
detected as much as 250 µm below the surface of soft tissue.  XRF is therefore 
in theory more prone than CT to detection of calcified tissue that over-lies or 
under-lies the cut section, though in practice this did not appear to be a 
significant problem. 
Spatial resolution, sensitivity, and acquisition time for both CT and XRF are an 
equipment-specific trade-off.  In this case, the resolution of the CT was limited 
by the specimen pixel size of 33 µm.  The resolution of the XRF scanner used 
was limited by the 200 µm minimum collimator size.  However, segmentation of 
closely spaced particles is not a priority in this application, and the resolution of 
both CT and XRF scanners was adequate for locating individual 
microcalcifications.  Acquisition time for CT in this study was approximately 30 
minutes per specimen, though further work has shown that this could be halved 
with little sacrifice in image quality.  Acquisition time for XRF was longer, in the 
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range of 45 to 90 minutes, depending on specimen size; this is more difficult to 
reduce without an unacceptable reduction in either sensitivity or resolution.  
With this equipment, CT is a significantly quicker technique. 
2.6 Summary 
A systematic and accurate method to identify the location of microcalcifications 
in breast biopsy histopathology specimens is of great assistance in studying the 
chemical composition of these clinically important entities.  Both the CT and 
XRF methods described proved effective of locating calcifications in the surface 
of wax embedded tissue blocks.  Locations could easily be related either to the 
tissue outline within the wax block or to a coordinate system defined by fiducial 
markers.  These can be matched to locations in microtomed sections, enabling 
all calcifications present in the section to be studied. Both techniques proved 
effective, though CT offers some advantages in tissue and marker visibility, 
depth selectivity, spatial resolution, and speed. 
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3 Dual-Energy X-Ray Imaging 
3.1 Aims 
While experimenting with x-ray parameters for locating calcifications by CT 
scanning of tissue specimens, it became obvious that dual energy x-ray 
absorptiometry could theoretically be used to differentiate between calcifications 
of differing composition.  There is substantial emerging evidence that the 
chemical composition of calcifications varies systematically with 
pathology63,108,109.  If calcium/phosphorus ratio also differs between benign and 
malignant cases, then it may be possible to differentiate between them using 
dual energy mammography.   
The aim of this stage of the research was therefore to explore the theoretical 
potential for using dual energy x-ray absorptiometry to differentiate between 
calcifications of differing elemental composition, and to a conduct proof of 
principle experiment to demonstrate that it is possible to differentiate between 
calcium phosphates with dissimilar calcium to phosphorus ratios. 
3.2 Introduction 
3.2.1 Dual energy material decomposition 
The concept of using two x-ray photon energies for clinical material 
discrimination was first proposed in 1963 by Cameron and Sorenson124 in the 
second half of their seminal paper on what is now termed single photon 
absorptiometry (SPA), though the dual energy concept is almost invariably 
credited125–127 to later authors.  Since then, the comparison of x-ray attenuation 
of two or more photon energies has spawned a wide range of medical imaging 
techniques which can discriminate between materials of differing elemental 
composition.  Dual energy techniques take advantage of the fact that the curve 
of attenuation coefficient vs. x-ray photon energy varies between elements.  
The mass attenuation coefficient of a mixture or compound is simply the 
weighted average of its elemental components, hence the attenuation curve for 
any material can be simply constructed if its elemental composition is known.  
An example is shown in Figure 3-1, plotted from NIST tables of x-ray mass 
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attenuation coefficients for standard human tissues123.  At the lower end of the 
energy range plotted, photoelectric absorption dominates, which is strongly 
dependent on atomic number.  At the upper end, Compton (inelastic) scatter is 
the major contributor to attenuation, and in this energy range the attenuation 
coefficient only varies to a small degree between elements, since the photon 
energy is much greater than the outer electron binding energy.  It can readily be 
seen that linear combinations of high and low energy images can be used to 
separate out the contributions of bone and soft tissue.  This forms the basis of 
bone subtraction radiography.   
 
 
Figure 3-1 Mass attenuation coefficient of cortical bone and soft tissue vs. 
photon energy. 
3.2.2 Dual energy mammography 
In mammography, dual energy subtraction has been employed in two ways.  
The most common method is termed contrast enhanced digital mammography 
(CEDM), or sometimes contrast enhanced spectral mammography (CESM).  
This technique takes advantage of the fact that tumours typically display 
increased angiogenesis and tissue perfusion128. High-energy and low-energy 
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digital mammograms are taken using x-rays above and below the k-edge of 
iodine, after administration of an iodine-containing contrast agent.  Weighted 
subtraction can give an image of the contrast agent without the need for a pre-
injection image.  The conventional application of this technique requires two 
sequential images at different energies, and careful avoidance of movement 
between them.  However, photon counting detectors are just starting to be 
introduced into clinical practice,129 most notably in the Philips Microdose 
mammography system.  Layers within the same detector can discriminate 
between photons of different energy, hence a dual energy image can be 
obtained with a single exposure.  This effectively removes the need for precise 
immobilisation between images.  In addition, the need for only one exposure 
rather than two both reduces the radiation exposure to the patient.130   
 
The second dual energy mammography technique is similar to bone subtraction 
radiography, and has been proposed as a method for improved visualisation of 
calcifications.  Most commonly this involves combining a high and low energy 
image to reduce the contrast between fat and glandular tissue to zero, thus 
making the calcifications more easily visible against a uniform background.  
Most studies indicate that using current technology, the minimum detectable 
calcification size is in general no better than conventional single energy 
mammography, without increasing the radiation dose to an unacceptable 
level.131,132  However, it could increase visibility of calcifications in regions with 
complex background tissue structure.131  As with CEDM/CESM, single-shot 
spectral imaging using an energy discriminating detector has potential for 
increasing the practicality of this technique by eliminating the need for 
immobilisation between exposures. 
 
A third use of dual energy mammography is for quantification of breast 
density133. Accurate quantitative measurement is of interest since increased 
breast density on mammography is associated with a substantially increased 
relative risk of breast cancer134. 
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3.2.3 Calcium/Phosphorus ratio 
Interestingly the original paper on the dual energy technique by Cameron and 
Sorenson124 explicitly mentions its use to determine the Ca/P ratio of bone:   
“The primary mineral elements of bone are calcium and phosphorus, so, in 
principle, the Ca/P ratio for a particular bone could be determined by measuring 
Io*/I over the same point on the bone at two different photon energies.”   
This appears to have been forgotten until almost precisely the same technique 
was re-invented by Fountos et al 127 34 years later.   
The algebra involved in making the calculation can obscure the simplicity of the 
underlying concept; for instance the following equation for the Ca:P ratio in 
Fountos et al is: 
𝑚𝐶𝑎
𝑚𝑃
=
𝑙𝑛 [
𝐼𝑤(𝐸1)
𝐼𝑏 . (𝐸1)
] . (𝜇𝑃𝑂4(𝐸2). 𝜌𝐶𝑎𝑃𝑂4 − 𝜇𝑤(𝐸2). 𝜌𝑤) − 𝑙𝑛 [
𝐼𝑤(𝐸2)
𝐼𝑏 . (𝐸2)
] . (𝜇𝑃𝑂4(𝐸1). 𝜌𝐶𝑎𝑃𝑂4 − 𝜇𝑤(𝐸1). 𝜌𝑤)
−𝑙𝑛 [
𝐼𝑤(𝐸1)
𝐼𝑏 . (𝐸1)
] . (𝜇𝐶𝑎(𝐸2). 𝜌𝐶𝑎𝑃𝑂4 − 𝜇𝑤(𝐸2). 𝜌𝑤) + 𝑙𝑛 [
𝐼𝑤(𝐸1)
𝐼𝑏 . (𝐸1)
] . (𝜇𝐶𝑎(𝐸1). 𝜌𝐶𝑎𝑃𝑂4 − 𝜇𝑤(𝐸1). 𝜌𝑤)
× 3.0679 
Where: 
𝑚𝐶𝑎 𝑚𝑃⁄  Is the mass ratio of Ca:P 
𝐼𝑤(𝐸𝑖),   𝐼𝑏(𝐸𝑖) Are the transmitted intensities through soft tissue and 
calcified tissue at photon energy Ei 
𝜇𝐶𝑎(𝐸𝑖),   𝜇𝑃𝑂4(𝐸1),   𝜇𝑤(𝐸𝑖) Are the mass attenuation coefficients of calcium, 
phosphate, and water at photon energy Ei 
𝜌𝐶𝑎𝑃𝑂4 ,    𝜌𝑤 Are the densities of hydroxyapatite and water 
A simple graphical explanation makes the underlying principles rather easier to 
visualise.   
If attenuance* is defined as:  𝐷 = −𝑙𝑜𝑔10 (
𝐼
𝐼𝑜
) 
And     
𝐼
𝐼0
=  𝑒𝑥𝑝(−𝜇. 𝑡)   [Beer’s law] 
Then   𝐷 =
𝜇.𝑡
ln (10)
 
Or alternatively in terms of mass attenuation coefficient (MAC): 
   𝐷 = 𝜇/𝜌.
𝑥
𝑙𝑛 (10)
 
                                            
*
 'The term absorbance' (symbol: A) is sometimes used for this quantity, though this is 
misleading in this context where there are losses in transmitted radiation due to scattering as 
well as absorption.  In 1996 IUPAC endorsed the term 'attenuance' (symbol: D) in its glossary of 
terms, to replace the term extinction, 
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D = Attenuance,  I = Transmitted intensity,  I0 = Incident intensity 
µ = Linear attenuation coefficient,  t = Thickness 
µ/ρ = Mass attenuation coefficient, x = Mass thickness (mass per unit area) 
For a given pixel in a registered pair of images, the mass thickness is a 
constant, hence the ratio in attenuance between high and low photon energies 
is equal to the ratio between the mass attenuation coefficients.  This is intrinsic 
to the material, and independent of thickness.  Moreover, in a two component 
mixture, the total high/low attenuance ratio (D-ratio) of the object will be a mass-
weighted average of the component mass attenuance ratios. 
Mass attenuation coefficient curves for calcium and phosphate* are shown in 
Figure 3-2.  Since this is plotted on a log-log scale, the magnitude of both the 
photon energy ratio and the attenuance ratio (equal to the mass attenuation 
coefficient ratio) can be visualised directly from the chart.  
 
Figure 3-2  The attenuance ratio attributable to material components can be 
visualised directly from a log-log chart of mass attenuation coefficient vs. 
photon energy. 
                                            
*
 The justification for this simplification in the composition of nonstoichiometric calcium 
phosphates is that the balancing O and H make a trivial difference to the mass attenuation 
coefficients.  This is explained by Fountos et al.
127
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Different material compositions can be distinguished most easily by choosing 
high and low photon energies that maximise the contrast in attenuance ratio for 
the two materials. The difference in D-ratios between two materials, as a 
function of high and low photon energy, can more easily be visualised by 
differentiating the log-attenuance curves with respect to energy.  This is 
depicted in Figure 3-3.  The area under the curve between the two selected 
photon energies corresponds to the log of the D-ratio of each component, and 
the area bounded by the two curves and the two photon energies is proportional 
to the log of the ratio of the two D-ratios.  This visualisation could be useful in 
selecting appropriate high and low photon energies. From this it can be seen 
that a lower photon energy of less than ~101.25 ≈ 18 keV is counterproductive for 
Ca:P measurement. 
 
Figure 3-3  Gradient of log-MAC for calcium and phosphate with respect to log 
photon energy. 
It might be concluded from that for optimal discrimination between components 
the photon energies should be chosen to maximise the area depicted in Figure 
3-3.  However, there are other practical constraints limiting the accuracy of 
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measurements at high or low energies.  This is illustrated in Figure 3-4, which 
shows the transmission through a clinically realistic combination consisting of 
50mm of breast tissue and a 500µm thick calcification.  Calculations are based 
on NIST data for cortical bone123 (as an analogue for the calcification) and for 
NIST breast tissue*.  It can be seen that at low energies the % transmission is 
low, rendering the calculations susceptible to counting-statistic errors and 
detector zero-errors.  At high energies, the contrast between calcifications and 
background are low, which would amplify errors due to background subtraction.  
Calculation of an optimum range would require detailed knowledge of the 
characteristics of the detector used. 
 
Figure 3-4 Total x-ray transmission and Weber contrast†, as a function of photon 
energy, through 50mm of breast tissue and a 500µm thick calcification. 
                                            
*
 The attenuance values in the NIST tables for breast tissue appear to represent rather dense 
breast tissue with only a small proportion of fat, when compared with other published 
attenuation coefficients for fat and fibroglandular tissue in the breast
210
. 
†
 Also known as Luminance Contrast.  This is defined as (If – Ib)/Ib, where If is the intensity of the 
feature and Ib is the intensity of the background. 
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If the material of interest is not isolated but embedded in a matrix (as with a 
calcification in breast tissue), the attenuance attributable to the calcification 
needs to be separated from the attenuance due to the matrix.  A uniform 
background around the feature of interest can simply be subtracted.  
Background subtraction is also straightforward where the background can be 
reliably interpolated over a small feature such as a calcification.  Allowance also 
needs to be made for the fact that the calcification displaces matrix 
volumetrically rather than sitting on top of it.  This adjustment can simply be 
made by subtracting the linear attenuation coefficient of the matrix from the 
calcification, effectively giving an incremental attenuation coefficient for the 
material of the calcification.   
Theoretical D-ratios have been calculated for photon energies of 20keV and 
40keV for a range of stoichiometric calcium phosphate materials and plotted 
against Ca:P ratio in Figure 3-5.  Note that monocalcium phosphate and 
tetracalcium phosphate are not found in-vivo, but have been included to 
illustrate the extremes of Ca:P ratio of calcium phosphates.  Tricalcium 
phosphate is only found in-vivo in its magnesium stabilised form in whitlockite.  
Non-stoichiometric apatites with varying Ca:P ratio can also form, in which a 
variable proportion of the trivalent phosphate ions have been protonated to 
become divalent hydrogen-phosphate ions, and charge balance maintained by 
a combination of calcium ion and hydroxide vacancies.  A frequently used 
generic formula for this calcium deficient apatite is given as: 
Ca10-x(HPO4)x(PO4)6-x(OH)2-x   with 0 < x < 2. 
However, it has been suggested135 and confirmed136 that when Ca:P ratios of 
less than 1.5 (i.e. x > 1) that a different formula fits experimental data better: 
Ca9-y(HPO4)1+2y(PO4)5-2y(OH)  with 0 < y < 1 
D-ratios have been therefore calculated for photon energies of 20keV and 
40keV using the first formula for Ca:P ratio 5:3 to 3:2 (i.e. 0 < x < 1) and the 
second formula for Ca:P ratios 3:2 to 4:3 (i.e. 0 < y < 1).  These have been 
added to the plot in Figure 3-5. 
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The effect of carbonate substitution on D-ratios has also been calculated and 
plotted in Figure 3-5.  In Type-B substitution, which is generally believed to 
dominate in biological apatites, phosphate substitution occurs in the same way 
as hydrogen phosphate, i.e.: 
Ca10-x(CO3)x(PO4)6-x(OH)2-x   with 0 < x < 2. 
In one study showing a variation in carbonate substitution with pathology, mean 
carbonate levels in calcifications were found to be 2.1 wt.% in benign tissue and 
1.4 wt% in invasive carcinoma.  Points corresponding to these two levels of 
carbonate have therefore been plotted.  It can be see that according to this 
substitution model, increased carbonate levels increase the Ca:P ratio and 
decrease the D-ratio, though at the levels observed in breast calcifications, the 
effect is very small. 
 
Figure 3-5 D-ratio of stoichiometric calcium phosphates, calcium deficient 
apatite, and carbonated hydroxyapatite.  Abbreviations are given in Table 3-1. 
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Abbreviation Common name Formula 
MCPM Monocalcium phosphate monohydrate Ca(H2PO4)2.H2O 
DCPD Dicalcium phosphate dihydrate 
(Brushite) 
CaHPO4.2H2O 
OCP Octacalcium phosphate Ca8H2(PO4)6.5H2O 
TCP Tricalcium phosphate Ca3(PO4)2 
HA Hydroxyapatite Ca10(PO4)6(OH)2 
TTCP Tetracalcium phosphate Ca4(PO4)2O 
CHAP Carbonated hydroxyapatite Ca10-x(CO3)x(PO4)6-x(OH)2-x 
Where x = 0.23 and 0.34 
Table 3-1  Abbreviations used in Figure 3-5 
 
Type I calcifications comprised of Calcium oxalate dihydrate (CaC2O4.2H2O), 
would have a D-Ratio of 5.92 for these photon energies, but is not depicted on 
this chart since the Ca:P ratio is infinite.  
3.2.4 Polychromatic radiation 
One simplification that has been made in this explanation is the assumption that 
the radiation used is monochromatic.  In SPA and DPA, this is achieved with the 
use of radioisotopes which emit radiation of a specific photon energy.  The 
isotopes used by Cameron and Sorenson124 were 125I (27.3 keV) and 241Am 
(59.6 keV), whereas Fountos et al127 chose 153Gd for high energy radiation, 
emitting at 97.5 and 103.2 keV (mean 99.9 keV).  Radionuclide sources have 
substantial disadvantages, not least cost, limited life, and impracticality for high 
resolution wide area imaging.  As a result, x-ray tubes superseded radionuclide 
sources for clinical densitometry by the early 1990s.  One disadvantage of an x-
ray tube as a source is that it generates polychromatic radiation, which is 
subject to beam hardening; this is a potential source of inaccuracy in 
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quantitative absorption measurements137.  However, choice of suitable filters 
can reduce such inaccuracies to a negligible level138. 
3.3 Proof of Principle Experiments 
3.3.1 Introduction 
3.3.2 Materials and Methods 
Discs were prepared from CamCeram III hydroxyapatite (CAM Bioceramics) 
which has a certified atomic Ca:P ratio of 1.667, and from calcium hydrogen 
phosphate* (Sigma Aldrich)  which has a Ca:P of 1.0.  Each powder was 
pressed into four Ø10mm discs with a nominal thickness of 0.3, 0.4, 0.7 and 1.0 
mm, using a Specac pellet die.  These were mounted on a 3mm thick PMMA 
sheet and mounted in a Nikon XT H225 CT scanner perpendicular to the beam.  
Tube voltages of 35kV and 60kV were found to give appropriate 
transmission/attenuation through specimens in the chosen thickness range. 
Three exposures were taken at each voltage: a dark frame (x-rays switched off), 
a white frame (x-rays on but sample out of view), and a sample frame.  The X-
ray flat panel detector (PerkinElmer XRD 1620) exhibits substantial ghosting 
and lag, typical of this type of amorphous silicon imaging panel139,140, hence 
care must be taken with quantitative measurements.  To address this, the dark 
signal from the panel was allowed to stabilise prior to all images.  The panel 
was deemed to have stabilised when the mean pixel dark signal reduced by 
less than 4 levels (in a 16 bit signal) in the previous 60 seconds.  That could 
take up to 30 minutes depending on the previous exposure.  White frame and 
sample exposures were started precisely 60 seconds after the x-rays were 
switched on.  This delay allowed the x-ray tube to stabilise and ensured that the 
panel signal only ramped up slowly during the exposure.  All stabilisation 
measurement and exposure timing was automated with a VBA program to 
ensure reproducibility. 
                                            
*
 Also known as also known as dicalcium phosphate or calcium phosphate, dibasic.  The IUPAC 
term is calcium hydrogen phosphate. 
 38 
Images were processed in ImageJ.  A transmittance image was created by 
subtracting the dark frame from the sample frame, then dividing by the pixel 
range given by the white frame minus the dark frame.  Pixel values were thus in 
the range of 0 to 1.  The other processing steps are shown in the results 
section. 
3.3.3 Results 
Images showing the processing steps are shown in Figure 3-6 
A 
 
Transmittance image with pixel values 
in range 0 to 1 
B 
 
Apply –log10 transform to obtain 
attenuance image. 
C 
 
Calculate median value of background 
from the region surrounding the discs 
and subtract from the image.  Apply 
global minimum attenuance of 10-6 to 
avoid a zero denominator in the next 
step. 
Calcium hydrogen phosphate (top row) 
Hydroxyapatite (bottom row) 
Aluminium step wedge 
 
Copper step wedge 
 
Not 
used 
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D 
 
Divide low energy attenuance image by 
high energy attenuance image to obtain 
an attenuance ratio image. 
Figure 3-6 Image processing steps to derive attenuance ratio image from two 
transmittance images. 
If a colour scale is applied to the image, it can be seen from Figure 3-7 that the 
top row, consisting of calcium hydrogen phosphate can be clearly distinguished 
from the bottom row consisting of hydroxyapatite, and that the different 
thicknesses of discs do not affect the D-ratio.  A histogram of mean D-ratio for 
the central 90% of each disc is given in Figure 3-8. 
 
Figure 3-7  Dual energy imaging clearly distinguishes discs of hydroxyapatite 
(bottom row) from calcium hydrogen phosphate (top row).  Labels refer to 
nominal thickness in mm. 
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Figure 3-8  Mean D-ratio as a function of material and disc thickness in mm. 
3.4 Summary 
The principle of dual energy material discrimination is well established and has 
successfully been used to differentiate between calcified tissue with different 
Ca:P ratios.  Spectral mammography is also increasingly used, though this is 
mostly used in conjunction with a contrast agent in CEDM/CESM, or less 
commonly, for improved visualisation of calcifications.  Theoretically, therefore, 
it may be possible to use this technique to differentiate between calcifications 
with a different Ca:P ratio.  The small size of the microcalcifications resulting 
from malignant processes in breast cancer does present some substantial 
technical challenges. 
Scattering of x-ray photons by breast tissue is a significant source of image 
degradation in mammography, and is a major obstacle to accurate quantitative 
measurement of attenuation141.  The scattered x-rays form a background which 
reduces the contrast of the image.  In conventional mammography, moving 
antiscatter Bucky-Potter grids are used to reduce the effect of scatter.  These 
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consist of high aspect-ratio lamellae that absorb scattered at angles greater 
than the acceptance angle of the grid.  These can greatly improve the image 
contrast, though there is still substantial residual scatter, particularly in thicker 
breasts.  Improved  scatter rejection constructs have been developed, and 
multi-slit collimation (as used in the Philips Microdose system) have 
demonstrated substantial reduction in the scatter-to-primary ratio compared to 
conventional mammography142.  Use of a pencil beam, as suggested by 
Ghammraoui et al 107, would further reduce the effect of scatter, though has 
obvious practical drawbacks. The accuracy of quantitative attenuation 
measurements can be further improved by the use of postprocessing algorithms 
to correct for residual scatter in the image141.   
The finite spot size of the source leads to loss of spatial resolution of the image.  
This is known as geometric unsharpness, and is likely to be a major challenge 
for quantitative measurement of attenuation in particles as small as breast 
calcifications.  Quantitative measurement of attenuation can only be made in 
the umbra, which requires the spot size to be small relative to the calcification.  
New developments such as liquid metal jet anodes47,50 may enable a sufficiently 
small spot to be used without an unacceptable increase in exposure time, which 
would itself run the risk of motion blurring. 
As with scatter correction, it is theoretically possible to use computational de-
blurring to compensate for a limited degree of geometric unsharpness.  The 
captured image is a convolution of the true image and the point spread function 
(PSF) of the system.  If the PSF can be measured, it is theoretically possible to 
reconstruct a de-blurred image by deconvolution.  In the absence of noise, this 
can be achieved by dividing the Fourier transform of the image by the Fourier 
transform of the point spread function.  However, in practice this simple 
approach is extremely sensitive to noise, and also requires the PSF to be very 
accurately known.  To overcome this, numerous deconvolution algorithms have 
been developed such as Wiener filtering or the Richardson-Lucy method.  
These are widely used in image processing, particularly in microscopy and 
astronomy.  However the main aim of these is to resolve closely spaced objects 
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rather than accurate reconstruction of grey levels, which is necessary for dual 
energy material decomposition.  
A challenge in dual energy imaging consists of accurate registration of high and 
low energy images.  This would be particularly critical for calcification imaging, 
since a very small shift in source, or breast, or detector would result in artefacts 
when combining the images.  Rapid cycling of the x-ray source voltage (known 
as rapid kV switching) is frequently employed in dual energy CT.  This has the 
advantage of minimising movement artefacts, but does have some limitations.  
It is difficult to cycle the tube current sufficiently quickly to balance the x-ray flux 
at high and low energies143.  In addition, it is not feasible to vary the anode 
material or to optimise the filtration for the two energies to minimise beam 
hardening, which is source of inaccuracy in quantitative absorption 
measurements137. A very promising new technology for spectral imaging is the 
energy discriminating photon counting detector129.  Rather than varying the 
source energy, the energy of transmitted photons is measured in the detector.  
This has even better immunity to motion and perfect image registration since 
high and low energy images are acquired in the same detector at the same 
time.  These detectors are in clinical use for mammography144. 
The challenges involved in using dual energy absorptiometry to differentiate 
between calcifications of differing elemental composition are substantial, but 
largely technological in nature.  One possible enabling technology is the use of 
liquid jet x-ray sources.  These have two theoretical advantages.  Firstly, the 
high energy density possible would enable a reduced spot size to be used 
without the penalty of a long exposure time. The consequent reduction in 
geometric unsharpness would help to achieve sufficient spatial resolution for 
quantitative measurement of attenuation.  In addition, the high intensity would 
enable more rigorous pre-collimation, such as in a slit or slot scanning 
configuration, or even a pencil beam, without excessive reduction in flux and the 
consequent unacceptable increase in exposure time.  This would help reduce 
attenuation error due to scatter.  Another enabling technology is the use of 
energy resolving x-ray detectors, allowing single-shot spectral imaging.  This 
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overcomes many potential problems with immobilisation and alignment of 
sequential images.  
For any of these there does need to be a diagnostically useful variation in 
elemental composition with pathology.  This is explored in the next chapter. 
 44 
4 Elemental Analysis 
4.1 Aims 
In order for dual energy x-ray absorptiometry, described in the previous chapter, 
to yield clinically useful information on calcification composition, there does 
need to be a detectable difference between calcifications in benign and 
malignant cases.  The principal aim of this phase of the research was therefore 
to determine whether there is a sufficient variation in Ca:P ratio with pathology 
for this parameter to have diagnostic potential. 
Secondly, despite the importance of calcifications in early detection of breast 
cancer, and the evidence that they may play an active role in breast cancer 
progression, our current understanding of the elemental composition of breast 
calcifications remains very sketchy.  Measurement of elemental composition 
and its relationship to pathology may offer insights into the processes involved 
in genesis and growth of these clinically important entities. 
Most of the content of this chapter has been previously published145. 
4.2 Background 
Qualitative elemental composition of breast calcifications has previously been 
studied using electron microscope x-ray spectroscopy63,84,88,90–92,146.  The 
majority of these studied calcifications that had been microdissected or digested 
from bulk soft tissue, though the two TEM studies used thin sections63,88, and 
one SEM study146 used frozen sections.  These qualitative studies mostly 
identified just calcium and phosphorus, though one found a higher incidence of 
calcifications containing magnesium in malignant specimens63, and two noted 
the presence of other elements such as and Na, Mg, Cl, K 84,92, and S, Si 84. 
One small semi-quantitative SEM-WDS study reported the Ca/P ratio of three 
benign and two malignant specimens, with an average of 9 spectra per 
specimen.  The authors reasoned that, although the specimens were porous 
and not polished, the effect of these drawbacks would be mitigated by 
calculating elemental ratios.  However, as discussed in the methods section of 
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this chapter, this is not a safe assumption since it is well established that low 
atomic number elements will be much more susceptible to shadowing than 
elements of a higher atomic number147. 
The level of magnesium in calcifications is of interest since studies have shown 
that magnesium levels both influence and are influenced by the process of 
carcinogenesis148,149.  Magnesium in breast calcifications has been detected in 
a previous study63, with the proportion of specimens containing magnesium 
increasing from benign to in-situ to invasive.  This observation may provide a 
clue as to why carbonate levels are lower in calcifications associated with 
cancer.  It has recently been shown that magnesium ions can strongly inhibit 
the incorporation of carbonate in hydroxyapatite 150.  Increased concentration of 
magnesium within cancer cells could lead to higher magnesium levels within 
calcifications, leading in turn to lower carbonate levels in calcifications 
associated with breast cancer. 
In contrast, significantly lowered serum magnesium levels have been found in 
breast cancer patients148, and it has been suggested that a low Mg:Ca ratio is 
risk factor in the development of postmenopausal breast cancer151.  A possible 
resolution of this apparent contradiction is that a peculiarity of tumour cells is 
their avidity for Mg, which accumulates within the cells even when extracellular 
Mg concentrations are low 
151,152
.   
4.3 Materials and Methods 
4.3.1 Archive blocks 
Formalin Fixed Paraffin Embedded (FFPE) core biopsy breast specimens were 
selected from the Gloucestershire Hospitals NHS Foundation Trust diagnostic 
archive (under approval from Gloucestershire Local Research Ethics 
Committee).  Blocks were randomly selected from the 2012 archive, subject to 
the presence of calcifications in the histopathology report, and an unambiguous 
classification of “B2 - Benign”, “B5a - Ductal Carcinoma In-Situ”, or “B5b - 
Invasive Carcinoma” 22.  For the purposes of analysis, specimens were also 
grouped as “Benign” (B2) vs. “Malignant” (B5a or B5b).  A summary of the 
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histopathology report for each of the specimens analysed is given in Appendix 
B.  These were screened by mounting the blocks in a Nikon Metrology XT H225 
CT system and imaging at 20 kV both perpendicular and parallel to the face of 
the block.  Following screening, blocks were selected with significant levels of 
calcification at or near the cut surface.  The selected blocks were then CT-
scanned, and the reconstructed volumes processed as described in Chapter 2 
to identify the position of calcifications relative to the tissue outlines at the 
surface of the blocks.   
4.3.2 Mounting 
Three sequential microtome slices of 5 µm were cut from each block.  The first 
slice underwent standard H&E (haematoxylin and eosin) processing, and was 
used for reference. Figure 4-1 shows typical H&E images of calcifications within 
specimens classified as B2, B5a, and B5b.  The second slice from each block 
was mounted on a polished Ø25mm aluminium alloy SEM stub, and was used 
for elemental analysis described in this chapter. The third slice was mounted on 
polyolefin heat shrink film for additional analysis by x-ray diffraction.  Full 
experimental details are described in Chapter 5. 
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Figure 4-1 H&E stained images of typical calcifications: (a) Specimen X44 (B2), 
(b) Specimen X53 (B5a), (c) Specimen X46 (B5b). Histopathology summaries can 
be found in Appendix B. 
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4.3.3 X-Ray microanalysis 
Elemental composition was measured using Energy-dispersive X-ray 
spectroscopy (EDS) in a Philips XL30 ESEM with an Oxford Instruments SiLi 
detector.  The working distance was 12mm, and approximately 200,000 total 
counts were taken per point measurement.  A total of 2,789 spectra were 
collected from 66 calcifications in 31 specimens.  Composition was calculated in 
AZtec 2.1 (Oxford Instruments).  Measurement of composition in this type of 
specimen presents several challenges, which must be addressed in order to 
obtain reproducible results. 
4.3.4 Charging 
It was initially hoped that a 5µm thick histological section in intimate contact with 
a polished aluminium SEM stub could be analysed under high vacuum without 
specimen charging, and indeed this proved to be the case with wax embedded 
soft tissue.  However, the calcifications were fragmented by the microtome 
blade, frequently resulting in elevated flakes with only an edge in contact with 
the substrate.  As a result, severe charging was observed with many 
calcifications.  This could not be eliminated by carbon coating, due to the 
fragmented nature of the surface.  Charging was eliminated by operating the 
SEM in environmental mode, with water vapour pressure 93 Pa (0.7 Torr).  This 
also removed the need for carbon coating.  Absence of charging was confirmed 
from observation of the Duane-Hunt bremsstrahlung limit.  One potential bias 
introduced by operating in environmental mode is scattering of the beam, and 
consequently contamination of point measurements with signals from the ‘skirt’ 
of scattered electrons.  With a working distance of 12mm and a 20kV 
accelerating voltage, only about 57% of the electron beam remains unscattered 
(scattering less than 10-6 Rad)153. In principle, therefore, measurements of a 
calcification could include a substantial contribution from surrounding soft 
tissue.  To assess the magnitude of this effect, the typical contribution from soft 
tissue in biopsy cores containing calcifications was measured.  Under identical 
collection conditions, soft tissue counts for phosphorus and calcium were 
approximately 2 and 3 orders of magnitude (respectively) lower than the counts 
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from a calcification, and magnesium was below the level of detection.  
Theoretically, therefore, the Ca:P ratio could be underestimated by up to ~0.4% 
in a very small calcification as a result of the contribution from the skirt.  In 
practice, this is substantially lower than other sources of variation for these 
measurements, hence can be disregarded.  For verification, measurements on 
a small (~Ø10µm) unfragmented calcification showed no significant variation in 
the Ca:P and Mg:Ca ratios with pressure over a range of 40 – 130 Pa (0.3 – 1.0 
Torr). 
4.3.5 Specimen thickness 
If the electron beam penetrates through the specimen to the substrate, this 
complicates the calculation of elemental concentrations, particularly if the local 
thickness varies within the skirt region of gas-scattered electrons.  This difficulty 
can be eliminated if the combination of specimen thickness and beam energy 
ensures minimal beam penetration to the substrate.  Using cortical bone as an 
analogue for the calcification matrix, the electron penetration depth of an 
unscattered 20kV beam into a 5µm thick slice was calculated using winCasino 
v2.48154.  This program is based on Monte Carlo simulation of electron 
trajectories in solids.  Elemental composition and density of cortical bone were 
taken from a NIST database123.  The curves in Figure 4-2 show normalised x-
ray intensity as a function of depth [commonly termed φ(ρz) curves].  This, and 
the corresponding energy density cross section in Figure 4-3, show that at 20kV 
and slice thickness of 5µm there is negligible penetration of electrons to the 
substrate.  A straightforward bulk analysis calculation can therefore be 
performed. 
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Figure 4-2 WinCasino 2.48 was used to create a φ(ρ,z) curve for generation and 
emission of Ca Kα x-rays  vs. depth with 20keV electrons into a 5µm layer of 
cortical bone.  It can be seen that there is negligible penetration of x-rays to the 
substrate. 
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Figure 4-3  Cross section view of absorbed energy density in a 5µm layer of 
cortical bone on an aluminium alloy substrate. 
4.3.6 Topography 
The chemical composition within breast calcifications has been found to be very 
inhomogenous155, hence an area measurement over the whole cut surface of a 
calcification is an attractive option for measuring the average composition.  
However, as a result of fragmentation by the microtome blade, the calcification 
surface is not smooth and perpendicular to the beam.  The local orientation of 
the surface relative to the electron beam and the detector can have a very 
substantial effect on the measured elemental concentrations.  Moreover, this 
effect is not symmetrical;  the disproportionate reduction in low energy x-rays 
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from areas tilted away from the detector is not compensated by the areas 
oriented towards the detector, hence simple area averaging over the whole 
calcification will underestimate the concentration of low atomic number 
elements.  The reduction in overall count rate from the areas tilted away from 
the detector mitigates this effect, but does not eliminate it. There are several 
strategies that can be adopted to correct for these topographic errors.   
One option is to measure the peak to local background ratio.  Since the 
background signal originates from the same electron interaction volume as the 
characteristic x-rays, it will be subject to the same absorption effects, and hence 
can be used to correct approximately for topographic errors.  A practical 
problem with this approach is that the peak to background ratio in this 
measurement configuration is typically large (50:1 for calcium in this case) thus 
an excessively long collection time is needed to acquire sufficient background 
signal to calculate an adequately precise peak to background ratio. 
Another approach is to take repeat point measurements in multiple specimen 
orientations, either by rotating the specimen around the beam axis, or with the 
use of multiple detectors.  A simpler alternative to obtaining an average 
composition for the calcification involves measurement of multiple points over 
the calcification surface; if the orientation of measurement points in the beam-
specimen-detector plane is symmetrically distributed relative the specimen 
normal, then the median measurement will approximate to the median 
composition with a surface orientation normal to the beam axis.  This was 
verified with measurements distributed over the surface of a 70µm spherical 
particle of synthetic hydroxyapatite.  In some cases there was evidence of 
systematic orientation of flakes comprising the calcification, due to the 
directional cutting action of the microtome blade.  A hybrid approach was 
therefore adopted, consisting of measuring multiple points, rotating the 
specimen by 180°, and measuring another set of points.  The median and 
confidence interval of the elemental ratios of interest was calculated for the 
combined set of points using Efron's nonparametric bias-corrected and 
accelerated (BCa) bootstrap method in R
156,157
.  Based on the 95% confidence 
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interval, the mean precision of the median for a set of measurements on a 
calcification was ± 3.4% for Ca:P ratio, and ± 16% for both Mg:Ca and Na:Ca 
ratios.   
4.4 Results 
4.4.1 Calcification Morphology 
An SEM-EDS image of a typical calcification is shown in Figure 4-4.  The 
aluminium signal derives from the substrate revealed by cracks in the 
calcification.  It can be seen that although the calcification has been fragmented 
by sectioning, it remains essentially complete.  As discussed in the methods 
section, a few calcifications were extensively disrupted by the microtome blade.  
An example is shown in Figure 4-5.  It can be seen that parts of the calcification 
have been lost.  Angled flakes of calcified material can be seen casting 
shadows in the secondary electron (SE) image, and can be seen to obstruct the 
aluminium signal from the substrate.  These calcifications with disrupted 
topography were generally characterised by a wider confidence interval for the 
median of measured composition.   
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Figure 4-4 SEM image of a typical calcification overlaid with EDS elemental 
maps.  The aluminium substrate can be seen through the cracks in the 
calcification resulting from sectioning.   
 
Figure 4-5 SEM image of a highly fragmented calcification.  Note the shadowing 
of the substrate in the Al image. 
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4.4.2 Calcium Phosphorus Ratio 
All bar one of the calcifications had a measured atomic Ca:P ratio in the range 
of 1.54 to 1.92, with a mean and median of 1.70.  The one Ca:P outlier 
consisted of a small (~Ø70µm) calcification in an invasive specimen, in which 
the Ca:P measurements fell into two very distinct groups: 15 point 
measurements had a measured Ca:P ratio >100, and 12 measurements had a 
Ca:P ratio in the normal range (median 1.78).  The normal and low-phosphorus 
measurements were in discrete areas, as shown by the calcium and 
phosphorus maps in Figure 4-6.  Although an isolated occurrence, the 
measurements from this calcification proved important in interpreting the results 
with minor elements. 
 
Figure 4-6  SEM image of a calcification with low phosphorus regions 
corresponding to a non-apatite phase. 
The relationship between pathology and the Ca:P ratio, averaged by 
calcification, is shown in Figure 4-7.  The mean Ca:P ratio was 1.70, 1.69 and 
1.70 for benign, in-situ, and invasive respectively.  In addition, the apparent 
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difference in variance between pathology groups was not found to be significant 
(Brown-Forsythe test).   
 
Figure 4-7 A plot of median calcification Ca:P ratios vs. specimen diagnosis 
shows no significant variation of Ca:P ratio with specimen pathology. 
4.4.3 Magnesium Calcium Ratio 
The mean Mg:Ca atomic ratio was calculated as 1.93% (95% confidence 
intervaI 1.70% - 2.11%).  The relationship between pathology and the Mg:Ca 
ratio, averaged by calcification, is shown in Figure 4-8.  Although 6 highest 
Mg:Ca levels out of 66 calcifications were all in specimens with an invasive 
diagnosis, there was no significant difference between the pathology groups. 
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Figure 4-8  A plot of median calcification Mg:Ca ratios vs. specimen diagnosis 
shows no significant variation of Mg:Ca ratio with specimen pathology. 
 
The single calcification with a very high Ca:P ratio showed a large difference in 
magnesium level between the low-P and high-P areas within the calcification.  
The 15 measurements from the low-P areas had a Mg:Ca ratio in the range 
0.1% - 1.1% (mean 0.7%), whereas the 12 measurements from the high-P 
areas had a Mg:Ca ratio in the range 1.8% - 2.7% (mean  2.2%). 
4.4.4 Sodium Calcium Ratio 
The relationship between pathology and the Na:Ca ratio, averaged by 
calcification, is shown in Figure 4-9.  Unlike the other two elemental ratios, there 
is a highly significant difference between groups.  Treating diagnosis as an 
ordinal variable, ranked benign < in-situ < invasive, the Na:Ca ratio is positively 
correlated with diagnosis (p < 0.001 Kendall’s tau-b ).  With the measurements 
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aggregated to a mean specimen level, the significance of the correlation 
becomes p = 0.007.  If diagnosis is treated as a binary variable, mean specimen 
sodium level is significantly lower in benign than malignant specimens (p = 
0.007 Mann-Whitney U). 
 
Figure 4-9  The Na:Ca ratio of calcifications in specimens with a benign 
diagnosis is significantly lower than that in specimens categorised as malignant 
(In-situ or Invasive). 
Measurements of sodium levels need to be treated with caution.  The 
specimens are immersed in saline solutions during fixation, hence at least some 
of the sodium present might not originate from the calcification.  However, the 
single calcification with areas of low-phosphorus calcified material provides 
evidence that the sodium detected is intrinsic to the apatite phase.  As with 
magnesium, the sodium measurements fell into two very distinct groups.  The 
15 measurements from the low-P areas had a low sodium content, with a Na:Ca 
ratio in the range 0.2% - 1.5% (mean 0.8%).  In contrast, the 12 measurements 
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from the high-P areas had high Na:Ca ratio in the range 3.3% to 6.4% (mean 
5.1% ).  This is shown in Figure 4-10. 
 
Figure 4-10  Scatter plot showing that low-P areas in specimen S66 also have a 
low Na:Ca ratio 
As confirmation that this is not an artefact in which the signal from all low atomic 
number elements is suppressed in the low phosphorus areas, or that an 
inadequately corrected oxygen sum peak is masquerading as sodium, the mean 
weight percentage of oxygen was 49% and 48% in the low and high 
phosphorus regions respectively. 
4.5 Discussion 
The calcium to phosphorus ratio was of primary interest in this study, since if 
there were a substantial variation with pathology, it would open up the 
possibility of additional diagnostically useful information from mammography 
using energy discriminating detectors.  However, the measured Ca:P ratio of 
calcifications found to lie in a narrow range (interquartile range 1.64 to 1.75), 
and no significant difference could be found between the pathology groups.  
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These results do not preclude the possibility that some diagnostically useful 
relationship may exist within a particular sub-type of calcifications, but the 
apparent lack of a general relationship limits the appeal of this approach. 
In the one previous semi-quantitative study of Ca:P ratio in breast 
calcifications96, the overall mean molar Ca:P ratios for the three benign and two 
malignant specimens measured were 1.64 and 1.67 respectively (weight ratios 
2.13 and 2.17) , which is very similar to these results. 
It has been suggested that the mechanisms involved in the formation of breast 
calcifications may be similar to those involved in the deposition of 
hydroxyapatite in bone; in particular, bone matrix proteins involved in osteoblast 
mineralisation are also expressed in mammary cells64.  Measured values for 
Ca:P ratio in bone vary widely, and have recently been comprehensively 
reviewed.158  The most relevant all-bone study cited is the ICRP-89 Reference 
Woman with a Ca:P atomic ratio of 1.63, and a compilation of studies on 
various bones gave a value of 1.68.  These are very similar to the values found 
for breast calcifications in this study.  Calcifications appear to be similar to bone 
in Ca:P ratio as well as in crystallographic parameters. 
The low phosphorus areas in one calcification must consist of a non-apatite 
phase.  The most likely contender is calcium oxalate, though without evidence 
from x-ray diffraction and/or vibrational spectroscopy, this cannot be confirmed.  
Although most calcium oxalate crystals have been reported in association with 
benign lesions, they have also been observed in malignant cases, where they 
are presumed to be bystanders86.  It is also notable that this instance occurs 
within a calcification which also contains regions of hydroxyapatite, whereas 
there are no previous reports of a mixed Type I/II calcification. 
The apparent absence of a relationship between magnesium content and 
pathology in these specimens is surprising in the light of the previous study 
showing increased magnesium in malignant specimens63, and the known avidity 
of tumour cells for Mg151,152.  One possible reason for the lack of a relationship 
in these specimens is the leaching of crystal-surface or hydration-layer 
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magnesium, either in-vivo or during histological processing.  This is discussed 
in detail in Chapter 5. 
One of the most interesting and potentially useful observations in this study is 
the presence significantly higher sodium levels in calcifications within malignant 
specimens.  This is consistent with the observation that total tissue sodium 
levels are elevated within breast tumours159,160.  Sodium readily substitutes for 
calcium in hydroxyapatite, and the level of substitution is likely to reflect the 
tissue sodium concentration at the time of apatite precipitation.  It appears that 
this difference survives histological processing, due to the fact that the sodium 
is substituted within the apatite lattice.  If it can be confirmed that all 
calcifications arising from malignant changes display elevated sodium levels, 
this has potential to indicate malignancy in the vicinity of a needle biopsy 
specimen, even if malignant cells are not contained within the core. 
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5 Crystallographic Parameters 
5.1 Aims 
Measurement of the elemental constituents of breast calcifications in the 
previous chapter only provides a limited insight into their composition.  
Biological calcified materials can present in a wide range of crystallographic 
phases.  Moreover, the crystallite dimensions and lattice parameters of any the 
phases may also vary with pathology.  The aim of this stage of the research 
was therefore to measure the phase composition and crystallographic 
properties of the calcifications using x-ray diffraction, and relate this to both 
diagnosis and elemental composition, in order to obtain a more rounded 
understanding of calcification composition. 
Most of the content of this chapter has previously been published161. 
5.2 Introduction 
To date, X-ray diffraction of breast calcifications has been limited to a qualitative 
identification of major phases present in small numbers of samples.  There have 
been no quantitative investigations of crystal lattice parameters and peak 
broadening, which provide information concerning ionic substitutions and 
crystallographic disorder respectively.  Moreover, investigations to date have 
relied on dissection of calcifications from bulk tissue specimens.  Any analysis 
relying on fresh tissue is hampered by the difficulty of accessing a wide range of 
specimens.  In contrast, diagnostic archives represent a rich source of material 
with varying pathology, and histological sections cut from archive blocks are 
readily available.  
It is technically challenging to acquire spatially-resolved X-ray diffraction data of 
sufficient quality for quantitative analysis from the very small volumes of poorly 
crystalline material present in these histological sections.  To the best of our 
knowledge, in-situ X-ray diffraction analysis on histological sections of any sort 
has only been reported twice before 162,163, in studies of vascular calcifications;  
this is the first time such a technique has been used to study breast 
calcifications.  The techniques developed could readily be used for investigation 
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of other pathological calcifications; similarities and differences may shed light on 
the mechanisms by which these are formed. 
5.3 Materials and Methods 
5.3.1 Archive blocks 
Formalin Fixed Paraffin Embedded (FFPE) core biopsy breast specimens were 
selected from the Gloucestershire Hospitals NHS Foundation Trust diagnostic 
archive (under approval from Gloucestershire Local Research Ethics 
Committee).  Blocks were randomly selected from the 2012 archive, subject to 
the presence of calcifications in the histopathology report, and an unambiguous 
classification of “B2 - Benign”, “B5a - Ductal Carcinoma In-Situ”, or“B5b - 
Invasive Carcinoma” 22.  For the purposes of analysis, specimens were also 
grouped as “Benign” (B2) vs. “Malignant” (B5a or B5b).  A summary of the 
histopathology report for each of the specimens analysed is given in Appendix 
B.  These were screened by mounting the blocks in a Nikon Metrology XT H225 
CT system and imaging at 20 kV both perpendicular and parallel to the face of 
the block.  Following screening, blocks were selected with significant levels of 
calcification at or near the cut surface.  The selected blocks were then CT-
scanned, and the reconstructed volumes processed as previously described 115 
to identify the position of calcifications relative to the tissue outlines at the 
surface of the blocks.   
5.3.2 Mounting 
As described in the previous chapter, three sequential microtome slices of 5 µm 
were cut from each block.  The slice used in this analysis was mounted on 
12.5µm thick polyolefin heat shrink film which was stretched taut over a 38mm 
diameter aluminium alloy ring, and held in place with an ‘O’ ring in a groove.  
The mounting method is depicted in Figure 5-1, and drawings of the fixture are 
in Appendix D.  
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Figure 5-1 – Tissue section mounted on polyolefin film stretched across an 
aluminium alloy ring, and held in place with a Viton rubber O-ring. 
Polyolefin heat-shrink film was chosen since it only exhibits weak diffraction 
lines, which are away from peaks of interest in candidate calcification phases.  
In addition, these lines are the same position as those from the paraffin 
embedding material. 
NIST (National Institute of Standards & Technology) Standard Reference 
Material 640c Silicon Powder was used for calibration of sample-detector 
distance.  A slurry was made with the standard powder in a dilute solution of 
PVA adhesive in distilled water, and three spots painted on the mounting film 
around and in the plane of the tissue section.   
Silicon standard spot 
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5.3.3 Beamline set-up 
X-Ray diffraction experiments were conducted on beamline I18 at Diamond 
Light Source, Didcot, UK.  Whilst in principle x-ray diffraction measurements 
could have been conducted using a laboratory source, synchrotron radiation 
offers substantial advantages for this type of research.  Firstly, the high 
brilliance possible with synchrotron radiation enables measurements to be 
made on particles such as breast calcifications, substantially quicker than even 
a high brightness laboratory source.  Secondly, instrumental broadening is 
typically insignificant relative to sample broadening in this type of specimen 
when using synchrotron diffraction, which minimises a potential confounder 
when performing peak broadening analysis.  Thirdly, we wished to investigate 
the variation in characteristics within individual calcifications, which requires a 
spatial resolution which is only realistically achievable with a microfocus 
synchrotron source. 
The aluminium sample rings were clamped perpendicular to the beam on a 
motorised stage.  Measurements were made in transmission using a Photonic 
Science X-ray sCMOS camera.  A video microscope was mounted at 45° to the 
beam and used to position the desired point on the tissue section in the beam.  
A beam spot size of 10x10 µm was used, with an energy of 10.0 keV.  The 
specimen to detector distance was kept constant by ensuring the centre of the 
microscope field of view was in focus at maximum magnification.  This was 
confirmed by measurements on each of the three silicon standard dots on every 
specimen.  Calcifications were located using the video microscope, by 
reference to the visible tissue outlines and the maps created from the CT 
measurements.  Measurements were made on typically 11 equally spaced 
positions in a vertical line from the bottom to the top of each calcification.  
Exposure was for 30 seconds per measurement.  Data acquisition was 
performed using the Diamond Generic Data Acquisition (GDA) software, with 
images and ancillary data saved in NeXus data file format.  A total of 548 
diffractograms were collected from 56 discrete calcifications in 15 specimens, 
consisting of 5 benign, 4 in-situ, and 6 invasive.  In addition diffractograms were 
collected for the silicon standards surrounding the specimens.  These sample 
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sizes are sufficient to achieve significant group differences using non-
parametric testing. 
5.3.4 Analysis 
Azimuthal integration of the 2D diffraction images to 1D patterns was conducted 
using DAWN (Data Analysis WorkbeNch) software 164.  The silicon standard 
images were used for calibration of beam centre, detector tilt, and sample-
detector distance. 
Diffractograms exhibited a large background to signal ratio, and it was found 
beneficial to subtract the background as a separate step prior to pattern fitting.  
The background was subtracted in R 165 using the Peak Filling method 166, with  
the background centred in the noise band.  Following background subtraction, 
pattern fitting was conducted using TOPAS 4.2 software (BRUKER AXS, Inc.). 
The whitlockite diffraction spots were separated from the continuous 
hydroxyapatite rings by cake-remapping in DAWN, followed by azimuthal 
background subtraction and azimuthal integration at each 2θ value in R.  This is 
similar to a method recently proposed for detection of abnormal grain growth in 
metals 167.  The whitlockite spots can be seen on a cake remapped diffraction 
image in Figure 5-2. 
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Figure 5-2 Cake remapped diffraction image showing whitlockite spots. 
The average percentage of whitlockite was calculated for each specimen from 
the total area of the two strongest whitlockite peaks, (0 2 10) and (2 2 0) at 2θ 
≈25.05° and 27.8° respectively, and from the total area of the overlapping (2 1 
1), (1 1 2), (3 0 0), and (2 0 2) hydroxyapatite peaks which lie in between.  
Those areas were converted to weight percent using Reference Intensity Ratios 
of Hydroxyapatite and whitlockite from the ICDD PDF-2 database 168.  However, 
it should be noted that the small number of whitlockite crystallites in a 
favourable orientation in each diffractogram will lead to inaccuracies in the 
relative area of each peak in the pattern.  
Typical whitlockite spots 
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The hydroxyapatite crystalline domain size was calculated from the fitted 
FWHM of the (002), (102), (210), (211), (112), (300), (202), (310), (222), (312), 
(213) peaks.  Decomposition of the heavily overlapped (211), (112), (300), (202) 
peaks was conducted in R.  This involved a least squares fit using fixed peak 
positions which were calculated for each diffractogram from the ‘a’ and ‘c’ lattice 
parameters from the whole pattern fit.  This gave a good fit for both broad and 
narrow peaks, as shown for illustrative purposes in Figure 5-3. 
 
Figure 5-3  Peak fitting using fixed component peak positions but unconstrained 
height and width gives a good fit to the major composite HA peak for both broad 
and narrow peaks. 
As is typical of synchrotron measurements on this type of material, instrumental 
broadening was negligible relative to the broad diffraction peaks, and was 
neglected.  All FWHM measurements were converted to Integral Breadth using 
the Lorenzian mixing factor of the fitted pseudo-Voigt peaks, using the 
formula169: 
𝛽 =
𝜋. 𝐻 2⁄
𝜂 + (1 − 𝜂)√𝜋. ln 2
 
 
Where β = Integral Breadth, H = FWHM, η = Lorenzian mixing factor 
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Integral breadth measurements were aggregated at specimen level as a 
weighted mean, using total area of the overlapped (211), (112), (300), (202) 
peaks as a weight.   
The apparent coherent domain thickness can be approximated using the 
Scherrer formula: 
𝜏 =
𝐾. 𝜆
𝛽. cos 𝜃
 
τ = apparent coherent domain thickness, λ = x-ray wavelength, K = shape factor  
K depends on the shape of the crystallite, and is frequently given the value 0.9 
based on an approximation of a spherical crystallite shape. In the case of 
anistotropic crystallites, as in these specimens, K varies with the direction of the 
diffraction vector.  To address this, the Scherrer formula can also be written 
as170,171: 
𝜀 =
𝜆
𝛽. cos 𝜃
 
Where ε = volume-weighted domain size in the direction parallel to the 
diffraction vector.  The value of ε can be calculated as a function of crystallite 
dimensions and diffraction vector angle for a range of crystallite shapes.  For a 
cylindrical shape172: 
Where 0 ≤ 𝜑𝑧 ≤ 𝛷 : 
𝜀 =
𝐷
𝜋
csc(𝜑𝑧) [
8
3
+ 2𝑞. 𝑐𝑜𝑠−1(𝑞) −
1
2𝑞
𝑠𝑖𝑛−1(𝑞) −
5
2
(1 − 𝑞2)1 2⁄ +
1
3
(1 − 𝑞2)3 2⁄ ] 
Or where ≤ 𝜑𝑧 ≤
𝜋
2
 : 
𝜀 = 𝐷 csc(𝜑𝑧) [
8
3𝜋
−
1
4𝑞
] 
D = diameter, H = height, 𝑞 = 𝐻. tan(𝜑𝑧) /𝐷 and 𝛷 = tan
−1(𝐷 𝐻⁄ ) 
φz = angle between reflection normal and cylinder axis 
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The apparent coherent domain size ε was plotted as the radial dimension in a 
polar plot against the angle of the reflecting plane normal to the crystallographic 
‘c’ axis.  A least squares fit line from the cylindrical model was fitted to the data 
points by adjusting D and H, and the best-fit cylinder length and diameter from 
the model used as the dimensions of the coherently diffracting crystallite 
domains.  Values of length and diameter were calculated from the weighted 
average integral breadth measurements aggregated by specimen.  For 
illustration of the method, best fit lines for the average for all specimens, broken 
down by diagnosis, are shown in Figure 5-4 
 
Figure 5-4 All-specimen average coherent domain thickness for each 
crystallographic reflection with Langford cylindrical model lines of best fit. 
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Inhomogeneous lattice strain from ionic substitution undoubtedly also 
contributes to peak broadening, and in theory it is possible to separate this from 
physical size effects by Williamson-Hall or Warren-Averbach methods.  
However, this is complicated by the fact that peak broadening in this case is 
markedly anisotropic, and the separation of anisotropic strain from anisotropic 
size effects requires data quality that is difficult to achieve with biological 
apatite.  As a result of this, and other unaccounted sources of peak broadening, 
the calculated size of the coherently diffracting crystallite domains is bound to 
be smaller than the physical size of the crystallites.  Indeed, it has been 
suggested that bone mineral is better described as paracrystalline, with a 
continuum of overlapping domains rather than crystallites with definite crystal 
boundaries 173.  Using coherently diffracting domain size, uncorrected for 
inhomogeneous strain, ensures comparability with the majority of studies on 
bone. 
5.4 Results 
5.4.1 Phase composition 
The predominant phase in these calcifications is nanocrystalline hydroxyapatite.  
This is clear from Figure 5-5, which shows a normalised sum of all background 
subtracted diffractograms, overlaid with the theoretical peak positions for 
hydroxyapatite 174.  These peak positions and intensities are tabulated in 
Appendix C. 
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Figure 5-5  All-specimens sum diffractogram and digitally isolated large 
crystallite diffractogram vs. theoretical line positions and intensities. 
In addition to the continuous Debye-Scherrer rings corresponding to 
hydroxyapatite, discrete diffraction spots were also observed in the 2-D 
scattering patterns, indicating the presence of a minor phase with substantially 
larger crystallites than the nanocrystalline hydroxyapatite major phase.  These 
diffraction spots were separated from the continuous hydroxyapatite diffraction 
rings, as described in the methods section, and the integrated diffractograms 
(Figure 5-5) confirm that this crystalline phase is whitlockite (a magnesium 
substituted calcium orthophosphate with a beta-tricalcium phosphate structure).   
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The relationship between pathology and the percentage of whitlockite within the 
calcifications, averaged by specimen, is shown in Figure 5-6.  With diagnosis 
treated as an ordinal variable ranked “benign” < “in-situ” < “invasive”, the 
percentage of whitlockite per specimen is positively correlated with diagnosis 
(p= 0.008 Kendall’s tau-b), i.e. the benign specimens contain the least 
whitlockite and the invasive specimens contain the most. 
 
Figure 5-6 Whitlockite weight percentage average per specimen, grouped by 
diagnosis.  Malignant specimens contain significantly more whitlockite than 
those with a benign diagnosis.  Individual specimen details are available in 
Appendix B.  
No evidence could be found of other crystalline phases.  In particular, the 
scatter angle region from 29° to 30° was examined for evidence of weddellite 
(calcium oxalate dihydrate) and brushite (calcium hydrogen phosphate 
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dihydrate), since this region is well separated from hydroxyapatite and 
whitlockite peaks and contains two major (> 10%) peaks each for weddellite 
and brushite.  Figure 5-7 shows the maximum intensity over all 548 
diffractograms, no peaks could be observed corresponding to these two 
phases. 
 
Figure 5-7  The maximum intensity line shows no evidence of any of the four 
peaks corresponding to brushite or weddellite which lie between 29° and 30°. 
5.4.2 Hydroxyapatite analysis 
Analysis of positions and widths of the intensity maxima in the diffraction pattern 
gives some insight into both the ionic substitutions in the crystal lattice and the 
size of the crystallites.   
The hydroxyapatite crystalline domain dimensions were calculated from the 
fitted peak widths as described in the methods section, and are plotted in Figure 
5-8.  With the diagnosis treated as an ordinal variable ranked “benign” < “in-situ” 
< “invasive”, the specimen mean crystallite domain ‘c’ axis length and ‘ab’ plane 
domain size both showed a positive correlation with diagnosis (p=0.034 and 
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p=0.011 respectively, Kendall’s tau-b).  With diagnosis treated as a binary 
variable, malignant specimens had larger ‘c’ axis length and ‘ab’ plane domain 
size than benign specimens (p=0.040 and p=0.005 respectively, Mann Whitney 
U). 
 
Figure 5-8  Hydroxyapatite crystalline domain dimensions, averaged by 
specimen and categorised by diagnosis. Malignant specimens have significantly 
larger crystalline domain size in both axes than benign specimens. 
The calculated ‘a’ and ‘c’ lattice parameters of the hydroxyapatite phase, 
averaged by specimen, are plotted in Figure 5-9.  There is a negative 
correlation, with a slope of ‘a’ vs. ‘c’ of -1.46 (95% confidence interval -1.87 to -
1.05).  With the diagnosis treated as an ordinal variable, as in the domain size 
analysis, the mean specimen ‘c’ lattice parameter showed a positive correlation 
with diagnosis (p=0.025, Kendall’s tau-b).  Using a binary analysis, the ‘c’ lattice 
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parameter is larger in malignant specimens than in benign (p= 0.019, Mann 
Whitney U).  The correlation between ‘a’ lattice parameter and diagnosis was 
not significant. 
 
Figure 5-9  Hydroxyapatite lattice parameters, averaged by specimen and 
categorised by diagnosis. There is a significant negative correlation between ‘a’ 
and ‘c’ lattice parameters, and the ‘c’ lattice parameter is significantly smaller in 
benign than in malignant specimens. 
5.4.3 Spatial variation 
Since the measurements were taken in uniformly spaced lines across each 
calcification, the position of each measurement in the sequence can be used to 
calculate an approximate proportion of the distance from the centre to the edge.  
The 002 FWHM (Full Width Half Maximum) of each measurement was 
normalised to the mean FWHM for that calcification, and plotted against position 
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in Figure 5-10.  The variation from the centre to the periphery was calculated by 
linear regression, and the regression line for each diagnosis plotted.  On 
average the 002 FWHM is 5.4% (2.6% - 8.2%) greater at the edge than the 
centre (p < 0.001).  This trend is very similar for benign, in-situ, and invasive 
specimens.  This indicates that the coherent domain size in the ‘c’ axis direction 
is larger at the centre of the calcifications than at the surface. 
 
Figure 5-10 The spatial variation of (002) FWHM shows that  the domain size is 
larger at the centre of the calcifications than at the surface. 
5.4.4 Correlation with elemental composition 
The crystallographic parameters measured were compared to the three 
elemental ratios reported in Chapter 4, in the 39 calcifications for which both 
sets of measurements were available.  These are shown in Table 5-1.   
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EDS 
Measurement 
XRD measurement Coefficient Adjusted R2 p-value 
Adjusted p-
value 
Mg:Ca ratio 
Whitlockite % -35.6 0.183 0.004 0.034 
Domain Diameter -125 0.165 0.007 0.046 
'c' / 'a' lattice parameter ratio -0.105 0.279 < 0.001 0.003 
Ca:P Ratio 
Whitlockite % 2.73 0.098 0.032 0.158 
Domain Diameter -0.0555 -0.028 0.991 1.000 
'c' / 'a' lattice parameter ratio 0.00231 -0.012 0.459 1.000 
Na:Ca Ratio 
Whitlockite % -1.29 -0.027 0.871 1.000 
Domain Diameter 63.1 0.107 0.026 0.154 
'c' / 'a' lattice parameter ratio 0.0366 0.071 0.056 0.222 
Table 5-1 Correlation of elemental ratios measured in this study, with X-ray diffraction measurements made on the same 39 
calcifications.
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The lattice parameter ‘c’ / ’a’ ratio was used since the ‘a’ and ‘c’ parameters are 
strongly negatively correlated in these specimens.  Linear regression was 
conducted with XRD measurements as a function of EDS measurements.  The 
p-value for a correlation was adjusted to control the familywise error rate for 
multiple comparisons using the Holm–Bonferroni method.  After adjustment, the 
only significant correlations between crystallographic parameters and 
composition relate to the magnesium calcium ratio.  Although the correlations 
are all weak, domain size, c/a lattice parameter ratio and whitlockite percentage 
were all significantly negatively correlated with magnesium concentration.  
5.5 Discussion 
5.5.1 Major phases 
The presence of calcifications consisting predominantly of nanocrystalline 
hydroxyapatite is unsurprising and concurs with previous X-ray diffraction 
characterisations.  Perhaps more surprisingly, no “Type I” calcium oxalate 
weddellite calcifications were observed in any of 56 calcifications analysed.  In 
addition, no calcium oxalate was found in 236 calcifications from 110 patients in 
an FTIR study of samples taken from the same archive 109.  Other studies have 
reported a widely varying proportion of calcium oxalate calcifications in biopsy 
tissue (e.g. 0.4%76, 7.3%77 , 17.3%80 , 28.8%63).  Although the specimen 
numbers in this pilot study were small, the absence of calcium oxalate in these 
results suggests a proportion towards the lower end of this range.  
5.5.2 Whitlockite 
The presence of whitlockite in these specimens is a novel finding.  It has 
occasionally been reported in other pathological calcifications, including 
prostate 175, aorta 176, cartilage 177, and salivary glands 178.  A cursory mention 
of a single FTIR observation in a breast calcification with an absorption band at 
990 cm-1 consistent with the presence of whitlockite was reported previously 179.  
Our study is therefore the first to make a positive confirmation of whitlockite in 
breast calcifications.   
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The occurrence of whitlockite implies the presence of magnesium, with the least 
whitlockite in benign specimens, and the most in invasive carcinoma.  The 
negative correlation between whitlockite fraction and Mg:Ca ratio shown in 
Table 5-1 is therefore initially rather surprising.  This can be explained from the 
nature of magnesium within calcified tissue.  Magnesium in bone resides largely 
on the crystal surface180,181 or hydration layer182,183 rather than within the apatite 
lattice.  Apatite has been shown to be capable of only very limited magnesium 
substitution under physiological conditions184.  Much of the magnesium in 
calcified tissue can therefore exchange rapidly, and forms the main reservoir for 
buffering extracellular magnesium in the body185,186.  Extracellular levels of 
magnesium have been observed to be, on average, lower than normal in breast 
cancer148.  Even if a calcification initially forms with high levels of magnesium, 
due to high intracellular levels, magnesium associated with hydroxyapatite 
could rapidly decrease towards the lower levels present in the extracellular 
environment.  This is particularly likely given the high surface area to volume 
ratio of a particle the size of a breast calcification.  It is also conceivable that at 
least some labile magnesium could leach from calcifications within the 
specimen through immersion during fixation and histological processing. 
In contrast to the apatite phase, the magnesium in whitlockite forms an 
essential stabilising element of the crystal lattice187,188.  The presence of 
whitlockite is therefore an indicator of the local magnesium concentration at the 
time of mineralisation, rather than the time of sampling162.  In precipitation 
experiments where there are both carbonate and magnesium ions in solution, it 
has also been observed that lower pH leads to less magnesium incorporation 
into the apatite lattice for a given magnesium concentration in the solution189.  
Furthermore, at lower pH, the appearance of whitlockite occurs at lower 
magnesium concentrations189.  The pH is, on average, likely to be lower in 
malignant specimens than benign, thus inhibiting incorporation of magnesium 
into the apatite lattice, and instead favouring whitlockite formation.  This offers 
an explanation for the increased whitlockite fraction in malignant specimens.  
The reported high intracellular151 vs. low extracellular148 levels of magnesium in 
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breast cancer would resolve the apparent contradiction that whitlockite 
percentage appears to be negatively correlated with magnesium content. 
Note that high intracellular levels of magnesium could still explain the low levels 
of carbonate observed in calcifications associated with tumours, as previously 
suggested161, since the carbonate level within the apatite lattice is influenced by 
the magnesium concentration at the time of crystallisation.   
5.5.3 Precursor phases 
Both brushite and octacalcium phosphate (OCP) have been identified as 
precursors to the formation of hydroxyapatite in mineralised tissue, particularly 
in an acidic environment190, which is typical of the microenvironment of solid 
tumours191.  No brushite was observed in these specimens.  OCP could not be 
distinguished from hydroxyapatite by X-ray diffraction in this study, since the 
patterns are nearly identical over the diffraction angular range captured.  The 
most prominent differentiating sign is the strong low angle OCP (1 0 0) peak 
with a d-spacing of 19.7  Å, which does not occur in hydroxyapatite.  However, 
this diffraction peak occurs considerably below the lowest angle collected in this 
study, and would require a different experimental setup to detect.  The presence 
of OCP cannot therefore be confirmed or ruled out in these specimens. 
5.5.4 Comparison with maturing bone 
It has been suggested that the mechanisms involved in the formation of breast 
calcifications may be similar to those involved in the deposition of 
hydroxyapatite in bone;  in particular, bone matrix proteins involved in 
osteoblast mineralisation are also expressed in mammary cells64.  It is therefore 
interesting to compare the observed characteristics of breast calcifications with 
those of bone in varying stages of maturity.  Calcifications in specimens with a 
benign diagnosis have smaller crystalline domains, a smaller ‘c’ lattice 
parameter, and a larger ‘a’ lattice parameter than specimens with in-situ or 
invasive carcinoma.  Hydroxyapatite crystallite domain size along the ‘c’ axis in 
human foetal bone has been shown to increase with increasing gestational age, 
accompanied by an increase in c/a lattice parameter ratio192.  This is shown in 
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Figure 5-11.  This increase in crystallite domain size dimensions continues up to 
the age of about 20 years, also accompanied by an increase in ‘c’ lattice 
parameter and decrease in ‘a’ lattice parameter193. 
 
Figure 5-11 Mean values of 
calcification c/a lattice parameter 
ratio (unit cell shape) and crystallite 
domain size along the ‘c’ axis  (τc) 
for benign and invasive specimens 
(green and red lines respectively), 
overlaid on corresponding 
measurements for foetal bone as a 
function of the average bone age.  
Foetal bone measurements 
reprinted from Dalconi et al 192, with 
permission from Elsevier. 
 
This combination of changes in lattice parameters and crystalline domain size 
with age in both foetal and child bone parallels our observations in breast 
calcifications from benign to in-situ to invasive.  The mean ‘c’ axis domain size 
in benign breast calcifications of 16.1nm is approximately equivalent to 17 week 
gestation foetal bone, whereas in invasive specimens the mean ‘c’ axis domain 
size of 19.9nm is approximately equivalent to bone at 23 weeks gestation.  In 
addition, the mean c/a ratio of 0.7286 in benign specimens is similar to that of 
foetal bone at gestational age of 16 weeks, whereas in invasive specimens the 
 83 
ratio of 0.7302 is similar to that of bone at 25 weeks gestation.  Of course these 
similarities do not imply a temporal progression in the breast calcifications, but 
may reflect comparable differences in chemistry.   
5.5.5 Ionic substitutions 
Lattice parameters can also give some insight into ionic substitutions within the 
crystal lattice.  Ionic substitutions within the crystal lattice invariably broaden 
peaks through inhomogeneous strain and restriction of crystallite growth.  The 
observation of broader peaks in benign specimens is therefore consistent with 
the increased carbonate substitution in benign cases as measured by 
vibrational spectroscopy108,109.  However, the lower c/a lattice parameter ratio 
observed in benign specimens is contrary to what would be expected with 
increased Type B phosphate-site carbonate substitution194,195.  Divalent 
carbonate ions can substitute either for monovalent hydroxide ions (Type A 
substitution) or for trivalent phosphate ions (Type B), or a combination of the 
two, and in conjunction with a range of charge balancing mechanisms such as 
Ca2+ or OH- ion vacancies and substitution of PO4
3+ by HPO4
2+ or Ca2+ by Na+.  
The nature of carbonate substitution in biological apatites is a complex and 
controversial topic, and has been the subject of a considerable research over 
many decades.  Early studies suggested that carbonate substitution in 
biological apatite is of Type B196, but recent studies have suggested that mixed 
A/B carbonate substitution is more consistent with FTIR evidence197–199, and 
that some of the apparent experimental disagreements arise from the shift of 
FTIR type A band frequencies into the spectral region of type B200.  Although 
carbonate is the most common substituent ion in calcified tissue, other ions 
such as magnesium are also present, and FTIR reveals an unexpected dearth 
of hydroxide ions201.  Lattice parameters are therefore difficult to interpret in 
isolation, and nature and location of substitutions would require further 
investigation using complementary analytical techniques in the same 
specimens, such as vibrational spectroscopy and elemental analysis. 
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5.5.6 Spatial variation 
The ‘c’ axis domain size is slightly larger in the centre of calcifications than at 
the edge. If maturation processes are similar to bone, with crystalline domain 
size increasing with time, this indicates that the material at the centre of a 
calcification is more mature than the material on the outside surface.  This 
observation does not appear to fit with the conjecture that ductal calcifications 
progressively occlude the lumen from the duct wall inwards.  As with the ionic 
substitutions, interpretation in terms of compositional difference would require a 
more in-depth investigation using additional analytical techniques. 
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6 Conclusions and Future Work 
6.1 Contributions to knowledge 
Research into the relationships between breast pathology and the physico-
chemical properties of breast calcifications requires access to a broad range of 
specimens, covering the growing array of breast cancer classifications and 
subtypes.  Studies using fresh specimens have been hampered by slow 
recruitment, and limited scope for sampling to avoid compromising pathology 
assessment.  In contrast, diagnostic archives offer a rich source of material for 
research.  In order to make use of this material, it is necessary locate the 
calcifications within the specimens. 
The first contribution of this research is a simple technique for systematically 
and precisely locating the position of calcifications within a histological section, 
described in Chapter 2.  Although apparently mundane, this proved to be a 
cornerstone for the rest of the research.  Without such a technique, much of the 
subsequent characterisation would have been difficult and haphazard.  This 
particularly applies to synchrotron experiments, in which beam time is very 
limited, and it is essential that as little time as possible is wasted hunting for 
calcifications. 
The synchrotron x-ray diffraction experiments reported here are the first ever 
XRD analysis of breast tissue histological sections, and apparently only the 
second report of x-ray diffraction experiments on histological sections of any 
type of tissue.   
A small proportion of magnesium whitlockite was discovered in the 
calcifications, with a substantially larger domain size than the apatite phase.  
Whitlockite has been reported in other types of pathological calcification but this 
is the first time that the presence of this phase has been confirmed in breast 
tissue.  The mean whitlockite proportion was found to be significantly higher in 
malignant specimens than in benign.  This may have potential as a marker of 
malignancy. 
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This was also the first diffraction study on breast calcifications to go beyond 
simple phase identification, and make quantitative measurements of 
crystallographic parameters.  These included coherently diffracting domain size 
(a proxy for crystallite size) and lattice parameters.  The analysis showed 
striking similarities in both these parameters between calcifications and newly 
formed foetal bone.  There was also a significant difference in both domain size 
and lattice parameter ratio between calcifications in benign and malignant 
specimens, with malignant specimens akin to a later stage of bone 
development.  This may be important since some breast cancer cells can 
develop osteoblast-like behaviour (osteomimicry), which is widely 
acknowledged to be a critical factor in the formation of metastases in bone.  The 
properties of calcifications in the vicinity of a tumour may provide an insight into 
the phenotype of the cells involved in calcification formation, which may be an 
indicator of propensity to metastasise. 
Previous elemental analyses of breast calcifications have been exclusively 
qualitative, with the exception of one semi-quantitative study on five specimens.  
Part of the reason for this is that there are many potential confounding factors 
affecting SEM/EDS measurement, particularly the fragmented calcifications 
found in histological sections.  A contribution of this work is the development of 
methods (albeit slow) for addressing these confounding factors.   
Elemental composition is of interest not only to help interpret the 
crystallographic parameters measured in the diffraction study, but also as a 
potential diagnostic or prognostic indicator in its own right.  Differences in 
calcium to phosphorus ratio could in principle be detected non-invasively by 
dual energy x-ray material decomposition, as discussed and demonstrated in 
Chapter 3.  However, the SEM/EDS experiments revealed that the Ca:P ratio is 
very similar in benign and malignant specimens.  Minor elements measured 
included magnesium and sodium.  The presence of these has previously been 
qualitatively reported in breast calcifications, but this is the first time these 
elements have been quantified.  Surprisingly, the Mg:Ca ratio did not differ 
significantly between benign and malignant specimens, though may be 
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explained by the labile nature of magnesium in apatite.  In contrast, the Na:Ca 
ratio was found to be substantially and significantly different between benign 
and malignant specimens.  This is consistent with other evidence that the 
sodium content of malignant cells is elevated.  The sodium level within 
calcifications may provide a useful marker of the intracellular sodium level at the 
time of calcification formation.  This marker appears to survive histological 
processing, opening up the possibility of studying this in a wide range of archive 
tissue. 
6.2 Future work 
The methods developed could be applied to investigate correlations between 
physico-chemical properties of calcifications and a wide range of breast cancer 
classifications and subtypes.  These include radiological classification of 
calcification morphology and distribution, and conventional pathology 
classifications such as nuclear grade and immunohistochemical grade.  In 
addition, linkage with cancer registries could in principle enable a direct 
correlation to be made with disease-free survival and mortality. 
Improvements have been identified that could increase the speed of 
measurement of both synchrotron XRD and SEM/EDS analysis, to expedite 
measurement of larger number of specimens.  The XRD experimental setup 
could be improved to eliminate shadowing artefacts and to collect both the small 
angle OCP (100) peak (OCP is a potential precursor of HA) and the HA (004) 
peak (to facilitate Williamson-Hall size-strain analysis). 
Complementary techniques applied to the same specimens would be useful to 
corroborate and expand on results from XRD and EDS.  Vibrational 
spectroscopy (Raman and/or FTIR) would enable a direct correlation between 
crystallographic parameters and anion substitutions, particularly carbonate.  
Laser Induced Breakdown Spectroscopy (LIBS) is a promising alternative 
technique for measuring elemental composition.  This has been used to 
measure the composition of bones, teeth, nails and calcified biomaterials202–204, 
and has also been used to discriminate between malignant and non-neoplastic 
soft tissue in the breast205,206.  This has the advantage of being very much faster 
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than SEM/EDS, and is substantially more sensitive for quantifying trace 
elements. 
The discovery of elevated sodium levels in malignant breast calcifications raises 
the possibility of measurement of soft tissue ion concentrations using micro ion 
electrodes207,208.  Potential applications include intraoperative margin analysis 
and biopsy needle guidance.  Measurement of sodium in calcifications could lay 
the groundwork for this, since this appears to act as a marker of soft tissue 
sodium content which survives histological processing.  Measurements could 
thus be conducted archival specimens representing a wide range of breast 
tumour characteristics such as size, type, grade, and IHC scores.  This could 
uncover the relationships between tissue sodium and pathology more quickly 
and easily than collecting a similar range of fresh soft tissue. 
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 A-1 
Appendix A Processed Data 
A.1 XRD Summary aggregated by calcification 
Spec. Calc. Diagnosis 
Lattice 
parameters /Å 
Whitlockite 
fraction 
Coherently 
diffracting 
domain size / nm 
c a H D 
X44 Calc 1 Benign 6.86843 9.46171 0.326% 15.91 10.26 
X44 Calc 2 Benign 6.87077 9.45310 0.388% 16.34 10.22 
X45 Calc 1 In-Situ 6.88030 9.43153 0.503% 18.28 11.91 
X45 Calc 2 In-Situ 6.88621 9.43238 0.868% 21.68 13.92 
X45 Calc 3 In-Situ 6.88854 9.44213 1.482% 16.49 15.10 
X46 Calc 1a Invasive 6.89079 9.42934 1.023% 22.77 16.07 
X46 Calc 1b Invasive 6.88482 9.43230 0.919% 21.67 15.15 
X46 Calc 2 Invasive 6.89058 9.42360 1.048% 26.22 18.43 
X46 Calc 3 Invasive 6.87955 9.43028 0.684% 19.59 13.39 
X46 Calc 4 Invasive 6.89510 9.41955 1.268% 25.38 18.20 
X46 Calc 5 Invasive 6.88761 9.42726 0.798% 20.82 13.42 
X46 Calc 6 Invasive 6.89618 9.41662 0.814% 20.43 14.60 
X47 Calc 1 Invasive 6.88802 9.43268 1.868% 19.09 13.68 
X47 Calc 2 Invasive 6.88354 9.43206 2.191% 16.58 14.61 
X47 Calc 3 Invasive 6.89206 9.43091 NA NA NA 
X47 Calc 4 Invasive 6.89190 9.43160 1.473% 17.36 11.82 
X48 Calc 1 Benign 6.87524 9.44294 0.284% 11.78 11.26 
X48 Calc 2 Benign 6.86580 9.44020 0.854% 12.51 11.22 
X49 Calc 1 In-Situ 6.88258 9.43016 1.349% 16.86 13.25 
X49 Calc 2 In-Situ 6.87777 9.44495 0.374% 13.35 11.12 
X49 Calc 3 In-Situ 6.87490 9.43103 0.279% 18.00 11.43 
X49 Calc 4 In-Situ 6.88506 9.42698 2.102% 14.89 16.05 
X49 Calc 5 In-Situ 6.87618 9.43282 0.656% 17.63 11.69 
X49 Calc 6 In-Situ 6.87438 9.44731 0.459% 18.47 11.66 
X49 Calc 7 In-Situ 6.88751 9.43151 3.151% 24.96 16.29 
X50 Calc 1a Invasive 6.88713 9.41062 0.868% 23.65 16.27 
X50 Calc 1b Invasive 6.89724 9.41638 1.545% 28.67 17.63 
X50 Calc 2 Invasive 6.88962 9.41256 0.566% 19.89 14.32 
X51 Calc 1 Benign 6.86702 9.44490 1.013% 18.83 10.40 
X51 Calc 2 Benign 6.87056 9.45599 0.679% 15.46 9.28 
X51 Calc 3 Benign 6.87129 9.45849 0.470% 14.67 9.26 
X52 Calc 1 Invasive 6.87652 9.45117 1.151% 18.98 11.38 
X52 Calc 2 Invasive 6.87698 9.43628 0.312% 18.78 11.89 
X52 Calc 3 Invasive 6.87408 9.45148 0.367% 20.06 11.82 
X52 Calc 4 Invasive 6.88021 9.43864 0.326% 18.62 11.73 
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X53 Calc 1 In-Situ 6.88600 9.42616 0.905% 19.96 13.83 
X53 Calc 2 In-Situ 6.86963 9.43537 0.724% 16.72 11.57 
X54 Calc 1 Invasive 6.88414 9.44075 1.054% 19.99 13.78 
X54 Calc 2 Invasive 6.88531 9.44135 0.673% 20.85 15.65 
X54 Calc 3 Invasive NA NA 3.096% NA NA 
X55 Calc 1 Benign 6.89028 9.43335 0.815% 20.51 18.11 
X55 Calc 2 Benign 6.89042 9.41657 0.723% 22.64 16.26 
X55 Calc 3 Benign 6.87286 9.42678 0.468% 18.44 12.27 
X55 Calc 4 Benign 6.89343 9.42128 0.671% 27.94 15.07 
X55 Calc 5 Benign 6.88754 9.43390 0.286% 16.85 10.55 
X55 Calc 6 Benign 6.88198 9.43320 0.406% 22.07 12.80 
X56 Calc 2 Invasive 6.88217 9.43308 0.382% 20.19 12.62 
X56 Calc 3 Invasive 6.88541 9.43002 0.856% 23.58 15.78 
X57 Calc 1 In-Situ 6.88628 9.42603 0.779% 22.10 13.67 
X57 Calc 2 In-Situ 6.88961 9.42303 1.413% 24.15 15.52 
X57 Calc 3 In-Situ 6.89103 9.42153 1.068% 23.53 15.13 
X57 Calc 4 In-Situ 6.89444 9.41933 0.904% 26.02 16.82 
X58 Calc 1 Benign 6.87215 9.44768 0.332% 15.86 10.60 
X58 Calc 2 Benign 6.86941 9.44911 0.266% 16.33 10.94 
X58 Calc 3 Benign 6.87855 9.43849 0.077% 15.02 10.41 
X58 Calc 4 Benign 6.87888 9.43288 0.177% 16.05 10.99 
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A.2 EDS summary aggregated by calcification 
Specimen Calc Diagnosis Spectra Mg:Ca Ca:P Na:Ca 
Median L 95% CI U 95% CI Median L 95% 
CI 
U 95% 
CI 
Median L 95% CI U 95% CI 
S43 Calc1 In-Situ 43 0.018072 0.015690 0.019278 1.7671 1.7350 1.7869 0.028797 0.026308 0.030023 
S44 Calc1 Benign 28 0.022179 0.018344 0.026424 1.7108 1.6597 1.7770 0.025773 0.020558 0.030847 
S44 Calc2 Benign 30 0.024192 0.021852 0.026755 1.6621 1.6145 1.7229 0.029700 0.024645 0.035815 
S45 Calc1 In-Situ 42 0.025125 0.023139 0.026893 1.6726 1.6345 1.7313 0.046824 0.036360 0.057301 
S45 Calc2 In-Situ 31 0.022076 0.018919 0.023830 1.6046 1.5682 1.6170 0.064742 0.058031 0.074476 
S45 Calc3 In-Situ 20 0.023854 0.017232 0.025984 1.6281 1.5832 1.7223 0.058439 0.041921 0.067050 
S45 Calc4 In-Situ 26 0.023362 0.021884 0.024826 1.5855 1.5543 1.6240 0.059910 0.051642 0.068704 
S46 Calc1 Invasive 60 0.014720 0.012875 0.015898 1.6808 1.6526 1.7274 0.057379 0.053764 0.061062 
S46 Calc2 Invasive 55 0.013913 0.012464 0.014577 1.6971 1.6653 1.7295 0.054727 0.045680 0.061547 
S46 Calc3 Invasive 63 0.018528 0.014787 0.019299 1.7316 1.6839 1.7676 0.050751 0.042707 0.055360 
S47 Calc1 Invasive 105 0.011137 0.009431 0.012904 1.8962 1.7894 1.9889 0.034632 0.029636 0.038570 
S47 Calc2 Invasive 128 0.014238 0.013167 0.015228 1.7812 1.7540 1.8241 0.042943 0.037820 0.047975 
S47 Calc3 Invasive 114 0.010835 0.009853 0.011940 1.8356 1.8028 1.8730 0.043555 0.040781 0.048584 
S47 Calc4 Invasive 178 0.013425 0.012607 0.014682 1.8037 1.7732 1.8319 0.033999 0.030153 0.036462 
S48 Calc1to2 Benign 50 0.025824 0.023921 0.026942 1.7389 1.7152 1.7811 0.035955 0.030481 0.039366 
S49 Calc1 In-Situ 21 0.013404 0.008750 0.014833 1.8412 1.6817 1.8540 0.035686 0.026284 0.048148 
S49 Calc2 In-Situ 20 0.015509 0.012105 0.017333 1.7068 1.6490 1.8689 0.044727 0.035252 0.053576 
S49 Calc3 In-Situ 17 0.013767 0.004355 0.017528 1.6139 1.5409 1.7221 0.062445 0.036419 0.083936 
S49 Calc4 In-Situ 11 0.012243 0.002538 0.018398 1.6597 1.5293 1.7934 0.046423 0.028352 0.061004 
S49 Calc7 In-Situ 22 0.009096 0.006435 0.012014 1.7996 1.7463 1.8324 0.034747 0.029750 0.038355 
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S50 Calc1 Invasive 22 0.017678 0.013027 0.023586 1.7239 1.6620 1.7755 0.066746 0.057056 0.081865 
S51 Calc1 Benign 39 0.026299 0.022958 0.028864 1.6926 1.6249 1.7436 0.025812 0.020898 0.029769 
S51 Calc2 Benign 23 0.025421 0.021581 0.027280 1.7247 1.6717 1.7416 0.029683 0.023705 0.034279 
S51 Calc3 Benign 23 0.023047 0.020647 0.025920 1.7783 1.6673 1.9254 0.026335 0.019588 0.031696 
S52 Calc1 Invasive 163 0.028205 0.023193 0.030091 1.7171 1.6865 1.7707 0.033993 0.030131 0.037122 
S52 Calc2 Invasive 97 0.052332 0.043490 0.057960 1.6242 1.5889 1.6560 0.045580 0.040852 0.050097 
S52 Calc3 Invasive 86 0.030092 0.027095 0.033724 1.6094 1.5829 1.6397 0.058323 0.052459 0.065676 
S52 Calc4 Invasive 112 0.031866 0.028791 0.035211 1.6344 1.5920 1.7024 0.062783 0.053424 0.070151 
S53 Calc3 In-Situ 44 0.023398 0.020439 0.024669 1.6662 1.6380 1.7105 0.051580 0.046026 0.054607 
S54 Calc1 Invasive 43 0.018174 0.016160 0.019359 1.6417 1.6127 1.6822 0.061773 0.057173 0.065231 
S54 Calc2 Invasive 23 0.025242 0.019011 0.025817 1.5424 1.5122 1.5707 0.069862 0.055822 0.086196 
S55 Calc1to4 Benign 29 0.013181 0.011625 0.014923 1.6517 1.6107 1.6921 0.031930 0.025968 0.033801 
S55 Calc5 Benign 63 0.007952 0.006620 0.009241 1.5782 1.5315 1.6240 0.060646 0.056169 0.067791 
S55 Calc6 Benign 15 0.021717 0.018381 0.023938 1.5918 1.4324 1.6437 0.044012 0.033802 0.075313 
S56 CalcCluster Invasive 45 0.018210 0.015894 0.019154 1.6126 1.5715 1.6446 0.061122 0.057712 0.067301 
S57 Calc1 In-Situ 43 0.012308 0.011238 0.013285 1.8234 1.7647 1.8728 0.028773 0.026304 0.032594 
S57 Calc2 In-Situ 54 0.012955 0.011336 0.013710 1.7740 1.7299 1.7939 0.034479 0.028417 0.037515 
S57 Calc3 In-Situ 27 0.012931 0.009802 0.014714 1.7197 1.6551 1.7918 0.030621 0.024171 0.040122 
S57 Calc4 In-Situ 40 0.009862 0.007968 0.011737 1.8100 1.7285 1.8525 0.031270 0.026005 0.038055 
S58 Calc1 Benign 34 0.016949 0.012806 0.019169 1.8598 1.8073 1.9996 0.026724 0.018006 0.027476 
S58 Calc2 Benign 31 0.024244 0.019454 0.028538 1.7501 1.6885 1.8266 0.033525 0.023031 0.036034 
S58 Calc3 Benign 25 0.023602 0.015065 0.026267 1.7363 1.6840 1.9645 0.027124 0.021235 0.034897 
S58 Calc4 Benign 19 0.022873 0.017718 0.023965 1.7664 1.6834 1.8381 0.036701 0.028948 0.040956 
S59 Calc1 Invasive 16 0.011549 0.009147 0.014186 1.9234 1.8112 1.9772 0.049192 0.042616 0.059591 
S59 Calc2 Invasive 24 0.014976 0.012676 0.018416 1.8087 1.6992 1.9109 0.062612 0.044163 0.070866 
S62 Site 10 Invasive 31 0.015593 0.009936 0.017166 1.6821 1.6429 1.7408 0.051725 0.037091 0.053657 
S63 Cluster1 Invasive 16 0.018538 0.015995 0.020678 1.7313 1.6849 1.7546 0.041347 0.037737 0.051396 
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S63 Cluster2 Invasive 44 0.017827 0.015902 0.018493 1.7397 1.7089 1.7621 0.045183 0.042135 0.048485 
S64 Calc1 Benign 16 0.006468 0.003994 0.008578 1.7124 1.6382 1.8074 0.035750 0.025339 0.040191 
S65 Calc1 In-Situ 14 0.011649 0.008264 0.013125 1.5695 1.5590 1.5791 0.067346 0.060663 0.072398 
S65 Cluster1 In-Situ 16 0.016180 0.012411 0.019230 1.6556 1.5720 1.6838 0.055667 0.046366 0.060618 
S66 Calc1 Invasive 26 0.021120 0.018641 0.022844 1.6739 1.6419 1.7065 0.063487 0.057581 0.069405 
S66 Calc2 Invasive 27 0.010543 0.006970 0.019693 41.6275 1.7952 66.1976 0.013337 0.007336 0.042081 
S66 Calc3 Invasive 12 0.020055 0.015381 0.022201 1.7784 1.7258 1.8414 0.046552 0.035066 0.049002 
S67 Calc1b Benign 23 0.005093 0.004257 0.006856 1.7067 1.6816 1.7842 0.056148 0.052876 0.062978 
S68 Calc1 Invasive 20 0.019962 0.018992 0.023316 1.6304 1.5937 1.6897 0.048641 0.041544 0.054559 
S68 Calc2 Invasive 11 0.008885 0.005561 0.011302 1.6257 1.4541 1.7559 0.060348 0.036638 0.074534 
S69 Calc1 In-Situ 25 0.013427 0.009809 0.016379 1.7110 1.5478 1.7864 0.061348 0.049767 0.081015 
S70 Calc1 Invasive 36 0.039323 0.030072 0.045177 1.6599 1.5592 1.7462 0.042178 0.034069 0.050083 
S70 Calc2 Invasive 17 0.035154 0.029737 0.042557 1.5978 1.5374 1.6819 0.046457 0.030143 0.050493 
S70 Calc2b Invasive 35 0.034891 0.028944 0.037422 1.6936 1.5836 1.7355 0.040004 0.028362 0.043495 
S71 Calc1 Benign 26 0.011585 0.009723 0.013298 1.7423 1.6915 1.8021 0.049278 0.040164 0.056581 
S72 Calc1 Invasive 42 0.014758 0.012284 0.016057 1.8917 1.8265 1.9604 0.028787 0.025797 0.029969 
S73 Calc1 In-Situ 72 0.019238 0.018298 0.020347 1.6842 1.6703 1.6943 0.042693 0.038281 0.045348 
S74 Calc1 Benign 32 0.028901 0.023048 0.031089 1.6526 1.6160 1.6892 0.032627 0.026906 0.034143 
S75 Calc1 Invasive 44 0.020341 0.016418 0.021840 1.6326 1.6012 1.6925 0.062747 0.055546 0.073652 
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Appendix B Pathology summaries 
 
Note:  Specimens for the EDS study were mounted on an SEM stub, and are prefixed with “S”.  The adjacent slices for the x-
ray diffraction study were mounted on polyolefin film and prefixed “X”.  
Specimen Histological 
Opinion 
Micro. Report:  Summary extract 
S43 B5a All three cores contain intermediate and high nuclear grade solid-type ductal carcinoma in-situ (DCIS) 
associated with some comedo necrosis and malignant microcalcification. There is cancerisation of lobules 
also present. There are some areas concerning for invasive malignancy but a definitive diagnosis cannot be 
made at this time. Immunohistochemistry will be carried out to see if this can be taken any further. At this 
time, the most appropriate categorisation is one of B5a.  Immunohistochemistry has been carried out and 
the areas of DCIS show rimming by myoepithelial cells. There is no definitive diagnosis of invasion and 
therefore the categorisation of B5a stands. Oestrogen receptor shows the DCIS to be strongly oestrogen 
receptor positive giving a quick score, if appropriate, of 8/8.  
S44 B2 Fibroadipose breast tissue including a fibroadenoma. Dystrophic calcification is noted within the 
fibroadenoma. There is no cytological atypia.  
S45 B5a Intermediate and high nuclear grade DCIS associated with malignant microcalcification.  DCIS shows solid 
cribriform and papillary growth patterns.  There is no evidence of invasive malignancy. 
 B-2 
S46 B5b High nuclear grade DCIS associated with malignant microcalcification and invasive ductal carcinoma which 
appears to be moderately differentiated. Immunohistochemistry for oestrogen receptors demonstrates 
that more than 67% of neoplastic cells of this tumour show strong nuclear positivity, giving a Quick score 
of 8/8. 
S47 B5b These fragments of breast tissue bear infiltrating carcinoma, on this evidence moderately differentiated 
ductal carcinoma comprising cohesive nests and cords of cells infiltrating hyalinised fibroelastotic stroma. 
The tumour does show some lobular features.  In addition there is high nuclear grade DCIS of solid and 
cribriform types with comedo necrosis and associated malignant calcification. Immunostaining for 
oestrogen receptors shows the tumour to be strongly ER positive (quick score 8/8). The tumour is E-
Cadherin positive supporting the diagnosis of ductal carcinoma. 
S48 B2 These biopsies are of breast tissue showing dense stromal sclerosis associated with coarse calcification 
which appears dystrophic. The epithelial elements show columnar cell change and mild usual type 
hyperplasia. There is no evidence of atypia or of in-situ or invasive malignancy in these biopsies. 
S49 B5a These breast core biopsies show intermediate nuclear grade ductal carcinoma in-situ of cribriform type 
with apocrine features. There is associated malignant microcalcification. There is no evidence of invasion 
in these biopsies.  
S50 B5b Cores of sclerotic and elastotic stroma which are infiltrated by a ductal carcinoma. The tumour appears 
well differentiated with well formed ducts lined by bland epithelial cells. There is much micro-calcification 
associated with the lesion and a small in-situ component is also present.  Immunohistochemistry shows 
strong nuclear positivity in almost all tumour cells for oestrogen receptor giving a Quick score of 8/8. 
 B-3 
S51 B2 The specimen comprises rather fragmented cores of benign breast tissue exhibiting a normal tubulo-
lobular architecture with quite marked hyaline fibrosis of the stroma.  There is some evidence of fibrosis of 
the intra-lobular stroma suggesting some fibrocystic change but some of the fragments show 
fibroadenomatoid features comprising expanded hyaline hypocellular stroma within which, there are 
some curvilinear compressed ducts. This fibroadenomatoid tissue is associated with large foci of micro-
calcification.  Although appearances may represent fibroadenomatoid change, part of a fibroadenoma is 
also a possibility. There is no evidence of malignancy.  
S52 B5b These core biopsies are infiltrated by a well differentiated ductal carcinoma (T1 P2 M2). There is 
associated microcalcification and focal DCIS. Immunohistochemistry for oestrogen receptors demonstrates 
that more than 67% of neoplastic cells of this tumour show strong nuclear positivity, giving a Quick score 
of 8/8. 
S53 B5a Histological assessment reveals that both specimens consist of cores of breast tissue within which there is 
high nuclear grade ductal carcinoma in-situ with a solid growth pattern associated with comedo necrosis 
and malignant micro-calcification. In areas, this has the features more in keeping with pleomorphic lobular 
carcinoma in-situ (LCIS) but, from a management point of view, should be regarded as DCIS.  There is a 
some scarring and inflammation associated with some of the ducts but there is no definite evidence of 
invasive malignancy, although, in specimen 2, is this more concerning and immunohistochemistry will be 
carried out and a supplementary report will be issued.  SUPPLEMENTARY: Immunohistochemistry has 
been carried out. There is no evidence of invasive malignancy. The in-situ component is negative for E-
cadherin. This is considered to pleomorphic lobular carcinoma in-situ (LCIS). From a management point of 
view, it should be treated as for DCIS. The categorisation of B5a remains. 
 B-4 
S54 B5b A core of desmoplastic fibro-elastotic stroma bearing infiltrating adenocarcinoma, on this evidence 
moderate to poorly differentiated ductal carcinoma. Some probable high nuclear grade DCIS showing 
comedo necrosis is seen and there is malignant calcification. Immunostaining for oestrogen receptors has 
been performed (1) revealing the tumour to be strongly ER positive (quick score 8/8). 
S55 B2 Stereo-cores right breast, representative calcs seen: This specimen comprises benign breast tissue 
exhibiting a normal tubulo-lobular architecture. There are well established fibrocystic changes with areas 
of fibrosis of the inter and intra-lobular stroma with dilatation and separation of acini. Apocrine and 
lactational type change is seen and in some areas, there is columnar cell change associated with benign 
micro-calcification. There is some cross cutting of the ducts. The specimen has been examined on multiple 
levels and neither in-situ nor infiltrating neoplasia is seen.   
S56 B5b This core biopsy shows a grade 1 infiltrating ductal carcinoma, not otherwise specified (tubules 1, 
pleomorphism 2, mitosis 1). Malignant microcalcifications are seen. There is no convincing DCIS.  ER Quick 
score is 7/8 (5 + 2). 
S57 B5a 1 and 2: Biopsies from both sites consist of breast tissue showing similar features with intermediate 
nuclear grade ductal carcinoma in-situ showing apocrine features. There is associated comedo necrosis 
with malignant microcalcification. There is no evidence of invasive malignancy in either specimen. 
S58 B2 These core biopsies show features of fibrocystic change with many areas of sclerosing adenosis and focal 
benign microcalcification. There is no evidence of epithelial hyperplasia, in situ or invasive malignancy. 
S59 B5b Contains infiltrating ductal carcinoma, poorly differentiated, Grade 3 (tubules 3, pleomorphism 3, mitoses 
2). There is no definite in-situ component but there is both necrosis and malignant calcification present.  
ER quick score of 7/8.  
 B-5 
S62 B5b Comprises cores of breast tissue bearing infiltrating carcinoma, on this evidence moderately differentiated 
ductal carcinoma.  The parenchyma bears a chronic inflammatory infiltrate and there is an intra-ductal flat 
and largely columnar cell proliferation showing variable atypia that in areas is considered to represent flat 
intermediate to high grade DCIS. Stromal micro-calcification is also seen.  Immunostaining for oestrogen 
receptors shows the tumour to be ER positive (Quick score 7/8).  
S63 B5b A core of fibroadipose breast tissue. There is marked stromal sclerosis within which there are breast 
structures that show some cystic change. Microcalcifiction is seen. One of the ducts is markedly dilated 
and another one shows columnar cell change.  Within the sclerotic stroma there are two or three 
epithelial profiles with nuclear enlargement. This develops into a small focus of invasive ductal carcinoma 
on the deeper levels.  Approximately half of the tumour cell nuclei are strongly positive for oestrogen 
receptors. Quick score 7/8. 
S64 B2 Cores of breast tissue showing fibrocystic change with some cystically dilated ducts, others that show 
columnar cell change and a stroma that shows hyalinosis in places. Benign microcalcification is seen in 
some of the dilated ducts.  
S65 B5a These breast core biopsies show high nuclear grade ductal carcinoma in-situ of solid type with comedo 
necrosis and malignant microcalcification. There is no evidence of invasive malignancy. 
S66 B5b These are cores of fibro-adipose connective tissue which show widespread infiltration by a poorly 
differentiated carcinoma with ductal morphology. In this material the tumour appears to be grade 3 (T3 P3 
M2). No conspicuous in-situ component is noted.Oestrogen receptor status is very weakly positive with 
only a small proportion of cells showing weak staining (Quick score 2/8).  
 B-6 
S67 B2 Tissue fragments comprising haemorrhagic adipose tissue together with breast tissue showing sclerotic 
stroma within which are benign ducts and lobules. Calcified material is seen associated with sclerotic 
stroma.  A small amount of epidermis is also present. No other lesion is identified.  Some dilated ducts are 
present on deeper levels and the appearances raise the possibility of sampling from an area of fibrocystic 
change. There is some calcification associated with these cystically dilated ducts. The appearances in this 
biopsy can be regarded as benign. 
S68 B5b Cores of breast parenchyma bearing focally necrotic infiltrating carcinoma, on this evidence poorly 
differentiated ductal carcinoma. There is high nuclear grade DCIS of micropapillary type with comedo 
necrosis.  Immuno staining for oestrogen receptors shows the tumour to be strongly ER positive (Quick 
score 8/8). 
S69 B5a Intermediate nuclear grade ductal carcinoma in-situ showing apocrine features. There is associated 
comedo necrosis with malignant microcalcification. There is no evidence of invasive malignancy. 
S70 B5b These core biopsies are infiltrated by a tumour composed of angulated tubules set in a desmoplastic 
stroma. This tumour is likely to be a grade 1 tubular carcinoma (tubules 1, pleomorphism 2, mitosis 1). 
Malignant micro-calcifications are seen. There is no DCIS.  Oestrogen receptor immunohistochemistry 
shows strong nuclear staining in all tumour cells. ER Quick score is 8/8 (5+3).  
S71 B2 Fragmented pieces of fibrofatty breast tissue plus some clot. There is evidence of fibrocystic change and 
columnar cell change and in one area, an aggregate of slightly ectatic separated acini are associated with 
benign calcification. Although one duct, in the most superficial levels shows some architectural 
complexity, this is considered an artefact due to cross cutting. The stromal collagen appears slightly 
fibrillary in areas but established elastosis is not seen.  
Neither in-situ nor infiltrating neoplasia is identified and a B2 diagnosis is considered appropriate.  
 B-7 
S72 B5b These core biopsies are widely infiltrated by a moderately differentiated ductal carcinoma exhibiting 
modified Bloom Richardson grade 2 features (T2 P2 M2). The tumour is associated with malignant 
microcalcification. There is no in-situ component identified in these biopsies.  Immunohistochemistry 
shows strong nuclear positivity in almost all tumour cells for oestrogen receptor, giving a Quick score of 
8/8.  
S73 B5a These core biopsies show foci of ductal carcinoma-in-situ exhibiting central comedo necrosis and 
malignant microcalcification. DCIS shows intermediate nuclear grade features. No evidence of invasive 
malignancy is seen in these core biopsies.  
S74 B2 These breast core biopsies show dense stromal sclerosis with benign microcalcification and some features 
on deeper levels of previous fat necrosis. The deepest level includes a cluster of cells within the fat which 
may be macrophages in association with the fat necrosis.  Immunohistochemistry has been performed and 
ovarall histological appearances are regarded as those of fibrocystic change with possible minimal focal fat 
necrosis and no atypical or neoplastic features. 
S75 B5b Cores contain infiltrating carcinoma which, on this evidence, is a classical lobular carcinoma which is 
moderately differentiated equating to a modified Bloom and Richardson grade of grade 2 (tubules 3, 
pleomorphism 2, mitoses 1) and is associated with lobular carcinoma in situ (LCIS) and malignant 
microcalcification.  Immunohistochemistry for oestrogen receptor shows moderate and focally strong 
staining in the vast majority of infiltrating carcinoma cells giving a Quick score of 7/8. 
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Appendix C Hydroxyapatite X-ray diffraction lines 
Relative intensity and d spacings are from the certificate of analysis for NIST 
Standard Reference Material 2910b Hydroxyapatite.  Φ = Angle between lattice 
plane normal and ‘c’ axis, based on lattice parameters for NIST 2910b. 
hkℓ I (relative) d (nm) 2θ (Cu Kα) 2θ (10 keV) φ 
100 10 0.8160 10.83 8.71 90.00 
101 3 0.5264 16.83 13.53 40.16 
110 2 0.4711 18.82 15.12 90.00 
200 6 0.4080 21.77 17.48 90.00 
111 5 0.3889 22.85 18.34 55.62 
201 2 0.3511 25.35 20.34 59.35 
002 34 0.3444 25.85 20.74 0.00 
102 8 0.3173 28.10 22.53 22.87 
210 15 0.3084 28.93 23.19 90.00 
211 100 0.2815 31.76 25.44 65.87 
112 48 0.2780 32.17 25.77 36.16 
300 60 0.2720 32.90 26.35 90.00 
202 21 0.2632 34.04 27.25 40.16 
301 4 0.2530 35.45 28.37 68.44 
212 6 0.2298 39.18 31.30 48.14 
310 22 0.2263 39.80 31.80 90.00 
221 2 0.2229 40.44 32.29 71.11 
311 6 0.2150 41.99 33.52 71.80 
302 1 0.2135 42.31 33.76 51.69 
113 5 0.2064 43.83 34.96 25.97 
400 1 0.2040 44.37 35.38 90.00 
203 4 0.2001 45.28 36.09 29.36 
222 28 0.1944 46.68 37.19 55.62 
312 20 0.1891 48.07 38.27 56.68 
320 4 0.1872 48.59 38.68 90.00 
213 30 0.1842 49.45 39.33 36.65 
321 15 0.1807 50.48 40.13 74.79 
410 11 0.1781 51.26 40.74 90.00 
402 12 0.1755 52.06 41.37 59.35 
004 13 0.1722 53.14 42.20 0.00 
104 1 0.1685 54.41 43.17 11.91 
322 6 0.1645 55.85 44.28 61.46 
313 4 0.1612 57.10 45.23 45.40 
501 2 0.1588 58.03 45.95 76.66 
412 1 0.1582 58.28 46.14 62.65 
330 1 0.1570 58.75 46.51 90.00 
420 4 0.1542 59.93 47.41 90.00 
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Appendix D XRD Fixture drawings 
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For use with3mm Section 34mm Bore 
VITON Rubber O-Rings 
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Appendix E ImageJ Programs 
This program processes CT scan output files from the CT Pro application 
(Nikon Metrology) of FFPE blocks with calcifications, and outputs six files: 
File name 
(* = specimen ID) 
Description 
Reslice *.tif Rotates and crops the volume so that slices are 
parallel to the surface of the wax blocks 
Preprocessed *.tif Brightness, contrast, and gamma adjusted. 
Reduced from 32 to 8 bit. 
*-Slice x.tif First complete slice selected at depth x. 
*-Slice x markers.tif Thresholded calcifications highlighted in red 
Montage slices x to x+6  *.tif Montage of first 6 complete slices 
*.txt Position coordinates of calcifications in first 
complete slice. 
 
 //Input: .vol file and .vgi file from CT reconstruction 
 //Pre-processing of vol file 
 //Select file 
 volFile = File.openDialog("Select .vol file"); 
 PreOrPost = getString("CT scan Post sectioning?", "n"); 
 if(PreOrPost=="y") 
 PreOrPost="Post"; 
 else  
 PreOrPost="Pre"; 
 
 //Read VGI file and extract voxel size 
 vgiFile=replace(volFile,".vol",".vgi"); 
 filestring=File.openAsString(vgiFile);  
 E-2 
 lines=split(filestring, "\n");  
 for(i=1; i<lines.length; i++){ 
 if (lines[i-1]=="[representation]"){ 
   columns=split(lines[i]," "); 
   sx=parseFloat(columns[2]); 
   sy=parseFloat(columns[3]); 
   sz=parseFloat(columns[4]); 
 } 
 if (lines[i-1]=="[resolution]"){ 
   columns=split(lines[i],"="); 
   voxmm=parseFloat(columns[1]); 
 } 
 }  
 
 //Import file 
 run("Raw...", "open=volFile image=[32-bit Real] width=&sx 
height=&sy offset=0 number=&sz gap=0 little-endian"); 
 //Set voxel size 
 voxum=voxmm*1000; 
 run("Properties...", "unit=um pixel_width=&voxum 
pixel_height=&voxum voxel_depth=&voxum"); 
 
 volTitle=getTitle(); 
 volPath=File.directory; 
 
 //Initial crop (unnecessary if CT reconstruction is of 
limited volume) 
 //setTool("rectangle"); 
 //waitForUser("Select rectangular region for rough crop"); 
 //run("Crop"); 
 
 //Straighten image 
 E-3 
 setTool("line"); 
 setSlice(round(nSlices*0.25)); 
 waitForUser("Draw line along bottom of face"); 
 getSelectionCoordinates(xb, yb); 
 x1=xb[0]; 
 y1=yb[0]; 
 x2=xb[1]; 
 y2=yb[1]; 
 xmb=(x1+x2)/2; 
 ymb=(y1+y2)/2; 
 z1=getSliceNumber(); 
 
 setSlice(round(nSlices*0.75)); 
 waitForUser("Draw line along top of face"); 
 getSelectionCoordinates(xt, yt); 
 x3=xt[0]; 
 y3=yt[0]; 
 x4=xt[1]; 
 y4=yt[1]; 
 z3=getSliceNumber(); 
 angZb=-atan((y2-y1)/(x2-x1))*180/PI; 
 angZt=-atan((y4-y3)/(x4-x3))*180/PI; 
 angZ=(angZb+angZt)/2; 
 xmt=xmb; 
 ymt=y3+((xmt-x3)/(x4-x3))*(y4-y3); 
 angX=atan((ymt-ymb)/(z3-z1))*180/PI; 
 run("Select None"); 
 run("TransformJ Rotate", "z-angle=&angZ y-angle=0.0 x-
angle=&angX interpolation=[cubic B-spline] background=0.0 
adjust"); 
 rotTitle=getTitle(); 
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 //Reslice and recrop 
 setSlice(round(nSlices*0.5)); 
 setTool("rectangle"); 
 waitForUser("Select rectangular region for recrop"); 
 dirChoice = getNumber("Reslice Direction: 1 for Top, 2 for 
Bottom", 2); 
 if (dirChoice==1) 
   direction="Top"; 
   else 
   direction="Bottom"; 
 run("Crop"); 
 run("Reslice [/]...", "output=1.000 start=&direction 
avoid"); 
 setTool("rectangle"); 
 setSlice(round(nSlices*0.1)); 
 waitForUser("Select rectangular region to crop"); 
 run("Crop"); 
 resliceTitle=getTitle(); 
 run("Flip Horizontally", "stack"); 
 saveAs("Tiff",volPath+resliceTitle+PreOrPost+".tif"); 
 selectWindow(volTitle); 
 close(); 
 selectWindow(rotTitle); 
 close(); 
 
 //Adjust grey levels and reduce bit depth 
 run("Gamma...", "value=0.50 stack");  // 0.5 is arbitrary, 
but visually appears the best 
 numSlices=nSlices; 
 
 // Find maximum intensity 
 E-5 
 run("Z Project...", "start=1 stop=&numSlices 
projection=[Max Intensity]"); 
 
 // Get grey value of 10th from most intense pixel (avoids 
outliers) 
 w = getWidth;  
 h = getHeight;  
 numpix=w*h; 
 a = newArray(numpix);  
 i = 0;  
 for (y=0; y<h; y++)  
   for (x=0; x<w; x++)  
     a[i++] = getPixel(x,y);  
 Array.sort(a);  
 maxlim=a[numpix-11] 
 close(); 
 
 //Find minimum intensity 
 run("Z Project...", "start=1 stop=&numSlices 
projection=[Min Intensity]"); 
 b = newArray(numpix);  
 i = 0;  
 for (y=0; y<h; y++)  
   for (x=0; x<w; x++)  
     b[i++] = getPixel(x,y);  
 Array.sort(b);  
 minlim=b[9]; 
 close(); 
 min=minlim; 
 max=maxlim; 
 setMinAndMax(min, max); 
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 run("8-bit"); 
 resliceTitle=getTitle(); 
 reslicePath=File.directory; 
 
 binTitle=replace(resliceTitle,"Reslice of ","Preprocessed 
"); 
 binFile=reslicePath+binTitle; 
 saveAs("Tiff",binFile); 
 
 //Output positions of marker holes and calcifications 
 inputPath=getDirectory("image"); 
 inputTitle=getTitle; 
 waitForUser("Select top slice"); 
 slice=getSliceNumber(); 
 toslice=slice+5; 
 run("Make Montage...", "columns=2 rows=3 scale=1 
first=&slice last=&toslice increment=1 border=1 font=14 
label"); 
 montageTitle=replace(inputTitle,"Preprocessed ","Montage 
slices "+slice+" to "+toslice); 
 montageFile=inputPath+montageTitle; 
 saveAs("Tiff",montageFile); 
 close(); 
 selectWindow(inputTitle); 
 run("Make Montage...", "columns=1 rows=1 scale=1 
first=&slice last=&slice increment=1 border=0 font=12"); 
 //Marker holes 
 //setAutoThreshold("Default"); 
 //run("Set Measurements...", "area centroid fit shape 
redirect=None decimal=1"); 
 //do{ 
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 //run("Analyze Particles...", "size=100000-250000 
circularity=0.8-1.00 show=Nothing display clear slice"); 
 //NB min size assumes measurement in microns 
 //holesFound = getString("All holes found?: y for Yes, 
other for No", "y"); 
 //if (holesFound != "y") 
 // waitForUser("Please adjust threshold"); 
 //} while (holesFound != "y"); 
 //resetThreshold(); 
 
 //waitForUser("Select calc positions slice"); 
 //calcslice=getSliceNumber(); 
 //calcifications 
 setThreshold(180, 255);  //180 is arbitrary 
 run("Threshold..."); 
 waitForUser("If necessary, adjust threshold"); 
 
 run("Analyze Particles...", "size=100-1E6 
circularity=0.00-1.00 show=[Overlay Outlines] display 
slice"); 
 particlesTitle=getTitle; 
 
 //Create results file name 
 sliceTitle=replace(inputTitle,"Preprocessed ",""); 
 sliceTitle=replace(sliceTitle,".tif","-Slice "+slice); 
 sliceFile=inputPath+sliceTitle; 
 
 //Save results file 
 saveAs("Results","C:\\Temp\\Tempresults.txt"); 
 File.rename("C:\\Temp\\Tempresults.txt", sliceFile + 
".txt") 
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 //Save slice image 
 selectWindow(particlesTitle); 
 saveAs("Tiff",sliceFile+".tif"); 
 resetThreshold(); 
 run("Flatten");  //makes overlay permanent 
 saveAs("Tiff",sliceFile+" markers.tif"); 
 selectWindow("Results"); 
 run("Close"); 
 selectWindow("Log"); 
 run("Close"); 
 selectWindow("Threshold"); 
 run("Close"); 
 close(); 
 close(); 
 close(); 
 //End of program 
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